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Dysfunction or deregulation of certain cellular processes is commonly used to distinguish 
known illnesses into separate and unique disease states. Although each cancer type is 
individually distinct, most cancers initially occur due to genomic mutations of oncogenes and 
tumor suppressor genes, leading to enhancement or disruption of specific cellular processes, 
including mitochondrial-mediated events. As an organelle necessary for both cell survival and 
cell death, the mitochondrion is involved in a variety of diseases, including cancer. Specific 
alterations to mitochondrial DNA in cancer can result in enhanced proliferation and avoidance of 
cell death pathways. Thus, alterations to mitochondria function often increase the likelihood of 
tumor progression.  
 In this dissertation, the role of a mitochondrial enzyme, 17β-hydroxysteroid 
dehydrogenase type 10 (HSD10), was examined in relation to cancer progression. In rat adrenal 
gland tumor cells, upregulation of HSD10 correlated with increased cell growth rate and tumor 
growth in mice, enhanced energy metabolism, and protection against oxidative stress-induced 
cell death. Downregulation of HSD10 in the rat adrenal gland tumor cells resulted in decreased 
cell growth rate, reduced mitochondrial bioenergetics, and increased vulnerability to cell death 
induction under both baseline and oxidative stress conditions. Reductions in cell growth rate and 
energy metabolism were also observed upon HSD10 knockdown in T47D human breast cancer 
cells, which supports the role of HSD10 in cancer across two different cancer types and species. 
Furthermore, overexpression of HSD10 did not transform MCF10A breast cells, providing 
evidence that HSD10 may not be a tumor-initiating factor. Together, the data suggest that 
upregulation of HSD10 promotes cell growth and resistance to stress-induced cell death 
specifically in cancer cells. 
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Overview of Cancer and Mitochondria 
In 2012, 8.2 million patients died of cancer, which was estimated to account for 15% of 
all deaths worldwide (1). The 2012 statistical report by the World Health Organization specified 
that approximately 32.6 million people were living with cancer worldwide, with 14.1 million 
new cancer cases diagnosed that year. Deaths from cancer worldwide are projected to continue 
rising, with an estimated 13.1 million deaths in 2030. Although overall cancer death rates have 
declined by 20% since climaxing in 1991 (2), this group of diseases is still of major importance 
regarding treatment and prevention. As cancer cells are continuously replicating, treatment 
regimens often fail to completely rid a patient of malignant cells, resulting in repopulation of the 
tumor (3). Thus, ongoing research is needed to stay ahead of this complicated disease.  
Cancer is composed of a vast group of diseases characterized by unchecked cellular 
proliferation and metastasis of abnormal cells throughout the body. The development of cancer is 
initiated by three known factors. First, genomic mutations constitutively activate oncogenes to 
promote uncontrolled cell growth (Schematic 1.1 (4)). Second, genetic modifications deactivate 
tumor suppressor genes so that they fail to inhibit the robust cell growth (Schematic 1.2 (5)). 
Third, stability genes necessary for genomic repair are inactivated, allowing for higher rates of 
mutations in the cellular genome (Schematic 1.3 (6)). All three genetic mutations allow normal 
cells to progress to cancer. Once cells become cancerous they exhibit large metabolic imbalances 
(7) and increased resistance to cell death (8), two processes regulated by mitochondria. As these 
organelles are vital players in the regulation of cellular function, it is plausible that they are 
involved in cancer development and progression (9). 
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Schematic 1: Tumorigenesis. Three genetic mutation types drive the conversion of normal cells 
to cancer cells. 1) Genomic mutations constitutively activate oncogenes to stimulate uninhibited 
cell growth. 2) Next, genetic alterations disable tumor suppressor genes so that they do not 
inhibit the robust cell growth. 3) Stability genes required for genomic repair are then deactivated, 
which allows for greater rates of mutations in the cell genome. 
 
Mitochondria are double-membrane-bound organelles composed of an outer membrane 
(OM) and an inner membrane (IM), which is further constructed into compartments: the 
intermembrane space, the cristae interior, and the matrix (10). Mitochondria are central players 
in cellular function with roles in sustaining cell survival, maintaining energy metabolism, 
balancing reactive oxygen species (ROS), and mediating cell death pathways. Given their 
extensive role in cells, mitochondrial function has been examined in many diseases, including 
cancer (11-13). Studying the functions of mitochondria in malignant cells, in comparison with 
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healthy cells, may help elucidate the modified mechanisms and molecular components involved 
in specific types of cancer. 
Otto Warburg was one of the first investigators to implicate mitochondria in cancer. His 
phenomenon, termed the Warburg effect, demonstrates that tumor cells exhibit increased 
glycolytic adenosine triphosphate (ATP) production and reduced oxidative phosphorylation 
(OXPHOS) (14). Since then, many aspects of the mitochondrion have undergone thorough 
investigation to shed light on the alterations promoting this aggressive disease. 
 
Altered Mitochondrial DNA in Cancer 
Mitochondria contain a DNA molecule (mtDNA) that encodes genes essential for normal 
mitochondrial function. Human mtDNA contains 37 genes that code for 13 polypeptides 
involved in respiration and OXPHOS, and two ribosomal RNAs in addition to 22 transfer RNAs 
important for protein synthesis (15). Furthermore, mtDNA has a noncoding region with a 
displacement loop for control of mtDNA replication and transcription (16). As mtDNA regulates 
vital processes, modifications to its genomic material have a profound impact on healthy cells. 
Numerous studies have reported the effects of mtDNA mutations in tumors. To begin, 
mtDNA copy number has been examined in diverse cancer types, indicating that changes in 
mtDNA content may be regulated in a tumor-specific manner (17, 18). Moreover, studies have 
shown that mutations in both the coding (19, 20) and non-coding (21-23) mtDNA regions are 
associated with cancer growth. Interestingly, these alterations strongly correlate with patient 
outcome (24), as displacement loop mutations typically correlate with lower survival rates (25). 
Thus, the severity of mtDNA alterations in cancer cells and patient endurance seem to depend on 
both mtDNA content deviations and mutation locations. 
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Modified Energy Metabolism in Cancer 
In healthy cells, ATP manufacturing is dependent upon oxygen consumption, the 
tricarboxylic acid (TCA) cycle, and the electron transport chain (ETC). Dehydrogenases of the 
TCA cycle are stimulated by mitochondrial calcium (Ca
2+
) intake (Schematic 2.1), which 
propels the reduction of nicotinamide adenine dinucleotide (oxidized NAD
+
 to reduced NADH) 
(26). In addition, succinate dehydrogenase, also known as complex II (succinate-ubiquinone 
oxidoreductase) of the ETC, catalyzes the oxidation of succinate to fumarate in the TCA cycle 
(27). ETC complex I (NADH-ubiquinone oxidoreductase) accepts electrons from NADH (28), 
while complex II receives electrons from succinate. Next, the electrons from complexes I and II 
transfer to complex III (ubiquinol-cytochrome c oxidoreductase) and are incorporated into 
cytochrome c (cyto c) for delivery to complex IV (cytochrome c oxidase) (28). This last complex 
reduces oxygen to water and plays a critical role in ATP synthesis (29). Protons are generated 
throughout the ETC process and used by ATP synthase (often referred to as complex V) in the 
OXPHOS pathway to synthesize ATP from adenosine diphosphate (ADP) and inorganic 
phosphate (30). Once produced, ATP propels many activities in the cell, including signal 
transduction, active transport, and DNA synthesis. Consequently, changes in energy production 





Schematic 2: Mitochondrial function in normal cells. Under regular oxygen conditions, 
healthy cells primarily rely on mitochondrial OXPHOS for ATP production. 1) Ca
2+
 ions are 
taken up into a mitochondrion through voltage dependent anion channels (VDAC) and Ca
2+
-
sensitive uniporter channels, and stimulate ATP generation. 2) Glucose is converted into 
pyruvate during glycolysis, 3) which is imported into the mitochondrion for entry into the TCA 
cycle. 4) Reduced succinate and NADH molecules are used in the ETC to power ATP 
generation. 5) ROS created along the ETC are balanced by anti-oxidants, such as superoxide 
dismutase (SOD). 6) Excess Ca
2+
 ions are expelled from the mitochondrion through the 
mitochondrial permeability transition pore (MPTP) comprised of VDAC, adenine nucleotide 
translocase (ANT), and cyclophilin D (CypD). Adapted from Carlson, E.A. et al. (2013) Drug 
Discov Today Ther Strateg (31). 
 
Warburg initially discovered that tumor cells display increased glucose uptake, enhanced 
glycolytic ATP generation, and diminished OXPHOS (7). Essentially, instead of utilizing 
pyruvate molecules in the TCA cycle to power the OXPHOS pathway for generation of ATP as 
is done by normal cells (Schematic 2.2-2.4), cancer cells convert pyruvate into lactic acid for 
energy generation (Schematic 3.1). A possible explanation for Warburg’s findings involves ATP 
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synthase malfunctioning as hyperglycemia in hepatocarcinoma cells reduced ATP synthase 
dimer stability (32). Also, Isidoro et al. found that expression of the β-catalytic subunit of ATP 
synthase is decreased in cancer cells (33), further implicating the involvement of complex V. 
Although the Warburg effect is widely recognized, several groups have challenged it by 
revealing that mitochondria in tumors are able to operate OXPHOS at lower capacities along 
with glycolysis (34). In fact, malignant cells can switch from a glycolytic state to OXPHOS 
under glucose-limiting conditions to adjust to changes in the cellular environment (35). Utilizing 
both respiration systems under diverse settings is important for tumor survival. For instance, 
glucose deprivation elevates OXPHOS in breast tumor cells while control cells remain 
unaffected (36). Conversely, hypoxia improves respiration in control cells whereas it is impaired 
in breast cancer cells (37), signaling for tumor cells to switch to glycolysis. Therefore, cancer 
cells can direct the energy metabolism systems according to their specific needs under a variety 











Schematic 3: Altered mitochondrial processes during cancer. In cancer cells there is a shift 
from OXPHOS to glycolytic ATP production, 1) producing large amounts of lactic acid via 
lactate dehydrogenase (LDH). 2) High levels of ROS induce carcinogenic mutations in mtDNA, 
but are 3) balanced by activated antioxidants. 4) Hexokinase (HK) inhibits opening of the MPTP, 
and as a result blocks cell death induction. Thus, the increased carcinogenicity and decreased cell 
death promotes cancer cell growth. Adapted from Carlson, E.A. and Yan, S.S. (2014) ICST (38). 
 
Balanced Oxidative Stress in Cancer 
Under homeostatic conditions, enhanced ATP production via increasing ETC activity 
propels the reduction of oxygen to water. Consequently, this contributes to greater leakage of 
free electrons from the respiratory complexes, resulting in the formation of superoxides, free 
radicals, and peroxides jointly known as ROS (39). As a compensatory mechanism, ROS 
scavenging enzymes are activated to eradicate harmful oxidants (40). Healthy cells tightly 
regulate the balance between oxidants and anti-oxidants to prevent destructive consequences 
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(Schematic 2.5). However, deficiencies in ETC complex activities are associated with depleted 
energy and heightened ROS production (41). Chiefly, reduced complex I, II, and IV respiratory 
capacities lead to increased risk of dysfunction (42). With low levels of ROS scavengers, 
harmful oxidants accumulate within the cell and cause damage, such as mtDNA mutations (43). 
Thus, unrestrained oxidative stress can propel cancer initiation and metastasis (44). 
Elevated oxidative stress has been observed in many different tumors, with persistently 
high ROS levels seen in malignant cells (Schematic 3.2) compared with paired controls (45). 
Accordingly, cells are able to use mitochondrial ROS as a mechanism to increase their chance of 
cancer development through a kind of pro-cancer feedback loop. Also, extra-mitochondrial ROS 
production can affect cancer behavior, correlating with enhanced tumor growth and invasiveness 
(46, 47). Thus, cancer cells are able to utilize enhanced intra- and extra-mitochondrial ROS 
generation to increase tumor developmental and metastatic abilities.  
However, elevated ROS levels can cause substantial damage to normal and cancerous 
cells alike. As a result, tumor cells are capable of rebalancing ROS production and elimination 
by activating antioxidants (Schematic 3.3) for restoration of an optimal redox state necessary for 
continuous proliferation (48). For example, it was found that increasing ROS caused inhibition 
of glycolytic enzyme pyruvate kinase M2, which in turn activated the antioxidant systems 
required for detoxifying ROS in cancer cells (49). Therefore, tumor cells regulate ROS levels not 
only for initial development, but for long-term management of cancer progression as well. 
 
Reduced MPTP Formation in Cancer 
A nonselective mitochondrial Ca
2+
-activated pore was initially discovered to take in and 
extrude ions during membrane permeability oscillations (50). Currently called the MPTP 
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(Schematic 2.6), it is often connected with cell death elicited by stress and Ca
2+ 
overload (51). 
Under stress conditions in healthy cells, the MPTP forms in the IM where its induction can lead 
to mitochondrial swelling, loss of transmembrane potential (ΔΨ), release of apoptotic mediators, 
and eventual cell death (52). However, MPTP-mediated cell death is suppressed in tumor cells, 
rendering them resistant to therapies (53). Many factors participate in protecting cancer cells 
from MPTP-regulated membrane disruption and cell death induction, a few of which are 
presently discussed.  
CypD is a prolyl isomerase located within the mitochondrial matrix and has been 
established as a modulatory component of the MPTP (54-56). Upon Ca
2+
 overload or oxidative 
stress in healthy cells, CypD translocation from the matrix to the IM activates the MPTP, 
inducing cell death (57). Interestingly, cancer cells overexpress CypD, which leads to the 
suppression of cell death by interacting with anti-apoptotic Bcl-2 (58). CypD-mediated inhibition 
of cell death also correlates with mitochondrial-bound HK molecules, as depicted in Schematic 
3.4. Inactivation of CypD results in the release of bound HK-II and enhances pro-apoptotic 
Bax/Bak-mediated apoptosis (59). Additionally, heat shock protein interactions with CypD 
inhibit normal CypD-dependent MPTP opening and cell death in some tumors (60). Thus, CypD 
seems to be involved in promoting cancer growth, and exhibits a variety of molecular 
interactions which aid in this.  
The translocator protein (TSPO; initially known as the peripheral benzodiazepine 
receptor) is another recognized component, first linked to the MPTP due to its ligand interactions 
(61). Moreover, the OM has been shown to have a regulatory role in MPTP formation, primarily 
through TSPO (62). As with CypD, TSPO is elevated in many types of cancer and in particular 
breast cancer (63). Intriguingly, increased levels of this protein are associated with enhanced 
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breast cancer invasiveness (64, 65), and correlate with shortened disease-free survival in lymph 
node-negative patients (66). It has been postulated that high TSPO levels may render malignant 
cells more resistant to MPTP formation and cell death, comparable to CypD. This is plausible, 
though additional research is required to determine the particular function of TSPO in cancer. 
Along with CypD and TSPO, two other channels were strongly suggested as constituents 
of the MPTP (67), but have since been shown to not be necessary for MPTP formation.  
Mitochondria take up small molecules and ions through VDACs on the OM (68). VDAC 
was originally hypothesized to play a role in MPTP configuration (69), however recent data 
suggests otherwise (70, 71). In cancer cells, VDACs are significantly upregulated; as expected, 
downregulation of VDAC directly affects proliferation (72, 73). HK expression is also linked 
with VDAC quantities as overexpression of HK-I and -II induces VDAC closure and prevents 
MPTP opening in cancer cells (74). This HK-mediated closure of VDAC may allow for CypD-
induced MPTP inhibition (Schematic 3.4), thus enhancing tumor cells’ proliferative abilities. 
ANT was another proposed component of the MPTP (75), as it functions to catalyze the 
exchange of mitochondrial ATP for cytosolic ADP through the IM (76). Nevertheless, studies 
demonstrated it is not essential for MPTP induction (77). Of the four ANT isoforms, increased 
levels of ANT-1 and -3 promote cancer cell death (78, 79), while high amounts of ANT-2 and -4 
contribute to malignant cell resistance (80, 81). Furthermore, ANT-2 seems to be critical for 
importation of glycolytic ATP in cancer cells (82). Interestingly, overexpression of CypD 
inhibits ANT-1-mediated apoptosis in tumor cells (83). Hence, the ANT isoforms oppositely 
participate in cancer, with CypD interactions vital in controlling cancer cell survival. 
Collectively, this suggests that interactions occur between MPTP components and other 
molecules for cancer cell survival; further investigation is needed for in-depth assessment.  
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Manipulated Cell Death Pathways in Cancer 
Two alternative pathways can initiate apoptosis within cells. The extrinsic route is 
triggered by death receptors on the cell surface (84), while the intrinsic path originates in 
mitochondria (85) (Schematic 4.1). Induction of apoptosis signaling stimulates initiator caspases 
(86), which activate executioner caspases for cleavage of death substrates (87). In mitochondria, 
anti-apoptotic Bcl-2 and Bcl-xL release tBid upon its activation by caspases (88). Pro-apoptotic 
Bax and Bak form multi-domain molecules after stimulation from tBid, propelling the release of 
cyto c and other factors from the MPTP (89). The apoptotic factors perpetuate the process, 
causing the organized collapse and shrinkage of the cell. Finally, the cell body is engulfed by 
nearby cells for removal (90). Also known as programmed cell death as it can be purposefully 
initiated, apoptosis is a cell death pathway that can be activated specifically by the 
mitochondrion. 
Most often, cancer cells display increased inhibition of apoptosis due to mutations that 
either disrupt pro-apoptotic proteins (91, 92) or elevate anti-apoptotic proteins (93). On the 
contrary, Smith et al. found that enhanced levels of pro-apoptotic Bad promote prostate cancer 
growth (94). This discrepancy illustrates that cancer cells tightly regulate all apoptotic protein 
levels according to their proliferative needs. Additionally, in the event of apoptosis initiation, 
some cancer cells can reverse the process and survive (8). Clearly, tumors manipulate many 
aspects of apoptosis to avoid cell death, which can render cancer therapies ineffective. As this is 
a major problem in cancer medicine, many groups are searching for treatments that target 
apoptosis. For instance, small molecule mimetics that inactivate anti-apoptotic proteins (95), 
concurrent inhibition of nuclear factor κB activity (96), and overexpression of tumor-suppressor 
protein p53 (97) are a few exploratory mechanisms by which apoptosis can be induced in tumor 
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cells. Simultaneously targeting cancer cell-specific apoptotic inhibitory pathways while 
administering anticancer agents may help to eliminate the resistance seen in tumors.  
 
 
Schematic 4: Mitochondrial-mediated cell death pathways in normal cells. In the event of 
cellular injury, a mitochondrion can signal cell death pathways for destruction of the damaged 
material or whole cell. 1) Apoptosis is initiated due to excessive Ca
2+
 and/or ROS levels. Bcl-2 
is inhibited by BH3-only proteins, allowing Bax and Bak to interact, inducing MPTP opening for 
Ca
2+
 and cyto c release into the cytosol. These apoptotic factors further propel the process until 
the cell collapses in an organized manner. 2) Necrosis results from ATP depletion and enhanced 
Ca
2+
 and ROS accrual. This leads to the loss of ΔΨ and eventual unplanned rupture of the cell. 
Adapted from Carlson, E.A. et al. (2013) Drug Discov Today Ther Strateg (31). 
 
In the event of cellular injury, an unplanned cell death pathway called necrosis can be 
launched (Schematic 4.2). Activation of death receptor adaptors leads to their translocation to 
the IM (98, 99). This disrupts the ANT-mediated ATP/ADP exchange, resulting in ATP 
depletion and ROS accumulation (100). Excessive levels of ROS and Ca
2+
 promote 
mitochondrial uncoupling, swelling, and disruption of ΔΨ via MPTP opening (101, 102). 
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Imbalances activate degradative enzymes that propagate the damage until the plasma membrane 
ruptures (103), leaking the intracellular contents in an unorganized manner.  
Studies have shown that necrotic cell death is impaired in cancer cells, although the 
particular mechanisms are still being examined. For instance, Nakagawa et al. found that 
inhibiting CypD protects malignant cells from necrosis (104). Also, although leucine zipper/EF 
hand-containing transmembrane-1 (LETM1) induces necrosis in normal cells, LETM1 
overexpression is common in many forms of cancer, leading to inhibition of necrotic cell death 
(105). Due to inconsistent outcomes with apoptosis-mediated treatments, several groups are 
focused on developing cancer therapies targeting necrosis. For example, enhanced expression of 
nuclear IM protein lamin B1 (106) and activation of DNA damage response pathways (107, 108) 
are two investigative components that induce necrosis upon anticancer agent administration. 
Potentially, the induction of necrosis may provide an alternative tool for treating cancer cells 












17β-Hydroxysteroid Dehydrogenase Type 10 (HSD10) 
 HSD10 is a mitochondrial enzyme that catalyzes the oxidation of a wide variety of 
substrates and is important in diverse disease states. Our group originally identified HSD10 as a 
single chain polypeptide capable of binding amyloid-β (Aβ) peptide (109), connecting it with 
Alzheimer’s disease (110). Table 1 lists all of the alternative names used for HSD10 in the 
literature.  
 
Alternate Names for HSD10 
Abbreviation Full Name 
ABAD Aβ-binding alcohol dehydrogenase (110) 
ERAB Endoplasmic reticulum-associated Aβ-peptide binding protein (109) 
HSD10 17β-hydroxysteroid dehydrogenase type 10 (111) 
HADH2 L-3-hydroxyacyl-CoA dehydrogenase type II (112) 
MHBD 2-methyl-3-hydroxybutyryl-CoA dehydrogenase (113) 
SCHAD Short chain 3-hydroxyacyl-CoA dehydrogenase  (114) 
SCHMAD Short chain L-3-hydroxy-2-methylacyl-CoA dehydrogenase (115) 
Table 1: Alternative names for HSD10 
 
As shown in Schematic 5A, the HSD10 gene is located on the short arm of the X-
chromosome (Xp11.2), spans approximately 3 kb, and is comprised of six exons (116). Exons 1-
3 form the NADH-binding domain at the N-terminus, while exons 4-6 at the C-terminus function 
to bind substrates and catalyze enzymatic reactions (Schematic 5B) (117). The HSD10 protein 
product consists of 261 amino acids, and is expressed ubiquitously in all tissues, but is most 
prominent in the liver, heart, and brain (109, 118). On the subcellular level, HSD10 is located in 
the mitochondrial matrix (119). Computational analysis of the HSD10 amino acid sequence 
revealed a mitochondrial localization signal at the N-terminus of the protein, ERLVGQ (120), 
for specific targeting of HSD10 to mitochondria. Eleven amino acids at the N-terminus form a 
positively charged amphiphilic α helix which aids in the mitochondrial import of HSD10 (111). 
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Schematic 5: HSD10 gene location and product structure. A. The HSD10 gene is located on 
the short arm of the X chromosome at position 11.2, specifically from base pair 53,431,257 to 
base pair 53,434,375; Adapted from NIH Genetics Home Reference (121). B. Computerized 
structure of HSD10 with N- and C-terminals labeled; Adapted from Powell, A.J. (2000) J Mol 
Biol (122). 
 
HSD10 belongs to the short-chain dehydrogenase/reductase superfamily, namely the 17β-
hydroxysteroid dehydrogenases (HSD17B). These alcohol oxidoreductases catalyze the 
dehydrogenation of 17-hydroxysteroids (123). Interestingly, HSD10 is the only HSD17B family 
member located in mitochondria. It can further catalyze NADH-dependent redox reactions of 
many different substrates, including β-hydroxybutyrate (BHB), fatty acids, linear alcohols, 
branched short chain acyl-CoAs, amino acid catabolites, and steroids (112, 124, 125). 
In healthy cells, HSD10 is a crucial component in the maintenance of cellular 
homeostasis, and overexpression of HSD10 has been shown to provide a protective effect in cells 
undergoing nutritional stress (126). As depicted in Schematic 6, the ability of HSD10 to 
metabolize vital substrates leads to an increase in energy production. Furthermore, sequestration 
of CypD by HSD10 likely aids in cellular protection by inhibiting cell death pathway initiation.  
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Schematic 6: HSD10 plays a vital role in the maintenance of cellular homeostasis. In healthy 
cells, HSD10 catalyzes the reactions of a variety of substrates, such as BHB and fatty acids, to 
propel mitochondrial respiration and increase ATP output. HSD10 also functions to break down 
isoleucine (ILE) and process branched-chain fatty acids. Additionally, HSD10 reduces cell death 
induction by binding and retaining CypD in the matrix. Adapted from Yan, S.D. and Stern, D.M. 
(2005) Int J Exp Pathol (127). 
 
It should be noted that the names ABAD and ERAB (Table 1) have recently gone under 
debate as new evidence suggests that this enzyme does not exhibit generalized alcohol 
dehydrogenase activity, and that it is not localized in the endoplasmic reticulum, respectively 
(128). However, it remains well established that HSD10 is present in mitochondria and has the 
ability to bind Aβ. Fundamentally, in view of the absence of an Aβ-rich environment in cancer 





Implication of HSD10 in Disease 
As HSD10 holds a significant role in healthy cell function, it is logical that HSD10 is 
important in disease progression. Indeed, alterations in HSD10 have been implicated in a variety 
of disease states.  
A very rare congenital neurodegenerative disease called HSD10 deficiency is caused by 
missense mutations in the HSD10 gene (129, 130) which impairs isoleucine degradation. The 
condition is X-linked, and predominately affects males. Of the seven known mutations which 
cause HSD10 deficiency, three have been investigated thus far. The R130C mutation causes a 
progressive neurodegenerative disease course beginning from 1 or 2 years after birth, and can 
lead to patient death within a few years. Symptoms include a progressive loss of motor and 
mental skills, and patients often develop epilepsy that is difficult to treat (131-133). The D86G 
mutation is associated with very severe neurological abnormalities, little psychomotor 
development, and extremely poor patient prognosis (134). Patients with the Q165H mutation 
display normal cognitive and motor development (134). At present, there are no available 
treatments for HSD10 deficiency. Additionally, a silent mutation in the HSD10 gene which 
affects splicing efficiency has been linked to mental retardation, choreoathetosis, and abnormal 
behavior (135, 136). 
Reductions in HSD10 levels in dopaminergic neurons have been observed in Parkinson’s 
disease (PD) patients (137), which is a neurodegenerative disease accompanied by the loss of 
dopaminergic neurons in the substantia nigra pars compacta. Using a PD mouse model, it was 
discovered that simultaneous overexpression of HSD10 has a protective effect on neurons, 
including improved mitochondrial respiration, ATP production, and MPTP inhibition (137). 
These PD studies suggest that HSD10 overexpression may be beneficial as a treatment method. 
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 HSD10 has been most prominently studied in Alzheimer’s disease (AD), which is 
characterized by dementia due in part to progressive nerve cell death in the human brain. 
Irregular Aβ production and its accumulation in Aβ plaques is a vital component in the 
pathogenesis of AD, although its role is not yet fully understood. The binding interaction 
between HSD10 and Aβ leads to disruption of HSD10 enzyme activity as the cofactor binding 
site is blocked (138, 139). HSD10-Aβ interaction has been observed in neuronal mitochondria in 
AD patients as well as in double transgenic amyloid precursor protein (APP)/HSD10 
overexpression mice (110).  Furthermore, AD-affected brain regions in patients exhibit elevated 
HSD10 levels (140). Interestingly, co-transfection of HSD10 and Aβ in cultured neurons results 
in increased apoptosis, which cannot be seen with HSD10 or Aβ treatment alone (141). 
Moreover, ETC complex IV activity is reduced in AD patients, leading to impaired energy 
metabolism (41). In transgenic APP/HSD10 mice it was shown that complex IV activity is 
diminished, ROS production is enhanced, cell viability is reduced, and rodent learning ability is 
decreased in comparison with transgenic APP mice (110, 142). Opposite of PD, these AD studies 









Involvement of HSD10 in Cancer 
Several HSD17B family members have been implicated in breast (143-145), endometrial 
(146), and colorectal (147) cancers, suggesting that this group of proteins is important in the 
pathogenesis of many different types of cancer. Recently, HSD10 was specifically shown to be 
elevated in certain forms of prostate carcinomas and osteosarcomas (118, 148), indicative of a 
potential role in cancer. Furthermore, HSD10 may promote tumorigenesis and aggressiveness, as 
elevated HSD10 levels were observed in prostate-to-bone metastases in comparison to non- 
malignant prostate and primary prostate tumor tissue (149). 
Additionally, a preliminary study performed by collaborator Dr. Hanina Hibshoosh 
revealed that human breast cancer tissue has higher quantities of HSD10, as shown by 
immunohistochemistry using Fast Red dye in Figure A. Since the adjacent normal breast tissue 
had minimal HSD10 staining, it is inferred that HSD10 overexpression is involved in breast 




Figure A: Preliminary data of HSD10 in human breast cancer tissue. A biopsy taken from a 
breast cancer patient was obtained and the tissue was stained for HSD10 protein using Fast Red 
Immunohistochemistry. Normal breast morphology is depicted on the left; cancerous tissue is 
shown on the right with enhanced staining of HSD10. Work by Dr. Hanina Hibshoosh. 
 
While HSD10 remains underexplored in all cancer types, the published data in bone and 
prostate cancers, in addition to the preliminary data in breast cancer tissue, strongly suggest that 
HSD10 may be utilized in cancer cells for protection against cell death induction and 








Interaction Partners of HSD10 
 As previously described, HSD10 can bind Aβ in vitro and in vivo in brains of AD 
patients, which leads to inhibition of many HSD10 enzymatic functions. Also detailed is the 
physical interaction between HSD10 and CypD in the mitochondrial matrix (127), which may 
prevent CypD translocation to the IM and ultimately block formation of the MPTP. 
 Additionally, HSD10 has been shown to bind to estrogen receptor α (ERα) in the 
mitochondria of rat cardiomyocytes (150), effectively blocking the metabolism of estradiol. As 
HSD10 converts potent 17β-estradiol (E2) to less potent estrogens such as estrone, it has been 
postulated that ERα regulates estrogen levels by mediating HSD10 activity. 
 Furthermore, two potential interaction partners have been identified using a yeast-2-
hybrid screen: PolyC binding protein 1 and ubiquitously expressed transcript (151). Further 













Purpose of this Dissertation 
HSD10 has been vastly studied in a variety of disease states, yet the role it plays in cancer 
development and resistance to anticancer treatments remains to be determined. This study should 
contribute to the understanding of the involvement of HSD10 in the development and growth of 
several cancer types, in addition to how cancer cells become increasingly resistant to cell death 
induced by therapeutics. 
Several published studies provide preliminary evidence suggesting that HSD10 is 
important in cancer development and aggressiveness. 
1. Certain malignant prostatic epithelial cells exhibited higher levels of HSD10 then non-
malignant control prostate cells (118), demonstrating that HSD10 is elevated in some 
cancer types. 
2. HSD10 gene expression was up-regulated in osteosarcoma patients classified as poor 
responders to chemotherapy (148), indicating a correlation between HSD10 and poor 
patient prognosis. 
3. Elevated HSD10 levels were observed in prostate-to-bone metastases compared to non-
malignant prostate and primary prostate tumor tissue (149), suggesting that HSD10 may 
promote tumorigenesis and aggressiveness. 
The aim of this work was to investigate the function of mitochondrial HSD10 in cancer 
cell growth and resistance to cell death. In order to elucidate whether HSD10 promotes cancer 
development, the cellular components involved and underlying mechanisms were identified, with 
particular emphasis placed on the interaction between HSD10 and CypD in cancer cells 
(Schematic 7). Furthermore, it was investigated whether HSD10 is involved in cancer cell 
resistance to cell death induction. 
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Taken together, these experiments are designed to help investigate the relatively 
unknown function of HSD10 in cancer cell growth and resistance to cell death. 
 
 
Schematic 7: Dissertation hypothesis for HSD10-mediated cancer cell growth. Top panel, 
cells overexpressing HSD10 bind to CypD and sequester it in the mitochondrial matrix, thereby 
avoiding cell death induction; this resistance allows for continued cancer cell proliferation. 
Bottom panel, cells under-expressing HSD10 cannot bind all of the available CypD; thus 
unbound CypD translocates to the IM where it induces cell death via MPTP opening. Adapted 













All chemicals used are listed in Table 2, all solutions created are described in Table 3, all 
equipment is recorded in Table 4, all assay kits utilized are listed in Table 5, and all enzymes, 
antibodies, and markers used are indicated in Table 6. Additionally, all oligonucleotides used are 
described in Tables 7 and 8, all plasmids utilized are recorded in Table 9, all cell lines used are 




2X Quick Ligation Buffer Roche 
5X Colorless GoTaq Reaction Buffer Promega 
10X TaqManRT Roche 
Acetyl CoA Sigma-Aldrich 
Bis-Acrylamide (30%) BioRad 
Ammonium persulfate (APS, 15%) Sigma-Aldrich 
Ampicillin (Amp) Sigma-Aldrich 
Antimycin A Sigma-Aldrich 
Blotto, non-fat dry milk LabScientific 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenol Blue Sigma-Aldrich 
Cholera toxin Sigma-Aldrich 
Chloroform Thermo Fisher Scientific 
Coenzyme Q1 Sigma-Aldrich 
Coenzyme Q2 Sigma-Aldrich 
Cytochrome c Sigma-Aldrich 
4',6-Diamidino-2-phenylindole (DAPI) Pierce 
2,6-Dichlorophenolindophenol (DCPIP) Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Dipotassium phosphate (K2HPO4) Thermo Fisher Scientific 
Disodium phosphate (Na2HPO4) Sigma-Aldrich 
Dithiothreitol (DTT) Active Motif 
dNTP  Roche 
n-Dodecyl β-D-maltoside Sigma Aldrich 
Dulbecco’s modified eagle’s medium (DMEM) Gibco Invitrogen 
DMEM/nutrient mixture F-12 medium 
(DMEM/F12) 
Gibco Invitrogen 
Epidermal growth factor (EGF) Sigma-Aldrich 
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Chemical Source 
Ethanol absolute (EtOH) Decon Laboratories 
17β-Estradiol pellets (0.36 mg/pellet; 45-day 
release) 
Innovative Research of America 
Ethidium bromide Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Fetal bovine serum (FBS) Gibco Invitrogen 
Fluoro-gel with Tris buffer Electron Microscopy Sciences 
G418 Supplement Sigma-Aldrich 
GeneAmp dNTP mix with dTTP Applied Biosystems 
Glycerol Thermo Fisher Scientific 
Glycine Sigma-Aldrich 
Hank’s buffered saline solution (HBSS) Gibco Invitrogen 
Horse serum Gibco Invitrogen 
Hydrochloric acid (HCl) Alfa Aesar 
Hydrocortisone Sigma-Aldrich 
Hydrogen peroxide (H2O2) Thermo Fisher Scientific 
Insulin Sigma-Aldrich 
IRDye 800CW 2-deoxyglucose (2-DG) Li-Cor Biosciences 
Isofluorane MWI Veterinary Supply 
Isopropanol Alfa Aesar 
Kanomycin (Kan) Sigma-Aldrich 
LB Agar Thermo Fisher Scientific 
LB Broth, Lennox BD Difco 
LE Agarose BioExpress 
Lentiviral Packaging Mix Sigma-Aldrich 
Lipofectamine 2000 Invitrogen 
Lipofectamine RNAiMAX Invitrogen 
Liquid Nitrogen Matheson Tri-Gas, Inc. 
Magnesium Chloride (MgCl2) Sigma-Aldrich 
D-Mannitol Sigma-Aldrich 
Methanol absolute (MeOH) Sigma-Aldrich 
MitoSOX Red Invitrogen 
MitoTracker Green Invitrogen 
MitoTracker Red Invitrogen 
N, N, N’, N’-tetramethylethylenediamine 
(TEMED) 
Thermo Fisher Scientific 
β-Nicotinamide adenine dinucleotide (NADH) Sigma Aldrich 
Opti-MEM medium Gibco Invitrogen 
Oxaloacetic acid Sigma-Aldrich 
Paraformaldehyde (PFA) Sigma-Aldrich 
Penicillin/Streptomycin (Pen/Strep) Gibco Invitrogen 
Phenylmethylsulfonyl fluoride (PMSF) Thermo Fisher Scientific 
Potassium chloride (KCl) Sigma-Aldrich 
Potassium cyanide (KCN) Sigma-Aldrich 
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Chemical Source 
Potassium dihydrogen phosphate (KH2PO4) Sigma-Aldrich 
Protease inhibitor cocktail set CalBioChem 
Protein assay dye reagent BioRad 
Random Hexamers Roche 
Restore Western blot strip buffer Thermo Fisher Scientific 
RNAse inhibitor Roche 
Rotenone Sigma-Aldrich 
Roswell Park Memorial Institute (RPMI) 1640 
medium 
Gibco Invitrogen 
Sodium Chloride (NaCl) Thermo Fisher Scientific 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich 
Solubilization solution Invitrogen 
Succinate Sigma-Aldrich 
Sucrose Thermo Fisher Scientific 
TaqMan universal PCR master mix Roche 
Tert-Butyl hydroperoxide (TBH) Sigma-Aldrich 
Tetramethylrhodamine methyl ester (TMRM) Molecular Probes 
Tris base Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
TRIZOL reagent Invitrogen 
Tryptone Sigma-Aldrich 
Yeast extract Thermo Fisher Scientific 
Table 2: List of chemicals used in this study 
 
Buffers, Solutions, and Cell Culture Media 
Solution Recipe 
BSA buffer 5% BSA, TBS 
Cell culture media 1 (HEK-293T, MCF7, 
MDA-MB-231, T47D) 
DMEM, 10% FBS, 100X Pen/Strep 
Cell culture media 2 (PC-12) RPMI-1640, 10% horse serum, 5% FBS,  
100X Pen/Strep 
Cell culture media 3 (MCF10A) DMEM/F12, 5% horse serum, 100X Pen/Strep, 
100 μg/ml EGF, 1 mg/ml Hydrocortisone,  
1 mg/ml Cholera toxin, 10 mg/ml Insulin 
Citrate Synthase assay buffer 100 mM Tris (pH 7.4), 0.17 mM Oxaloacetic 
acid, 0.2 mM Acetyl CoA 
Co-IP collection buffer 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.2% 
Triton X-100, 1 mM EDTA, 100X protease 
inhibitor, 100X PMSF 
Co-IP wash buffer 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.2% 
Triton X-100, 1 mM EDTA 
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Solution Recipe 
Complex I reaction buffer 5 mM MgCl2, 2 mM KCN, 0.13 mM NADH, 2 
µg/ml Antimycin; diluted in K buffer 
Complex II reaction solution 1 5 mM MgCl2, 20 mM succinate; diluted in K 
buffer 
Complex II reaction solution 2 2 µg/ml Antimycin, 2 µg/ml Rotenone, 2 mM 
KCN, 50 µM Dichlorophenlindophenol 
Complex III reaction buffer 5 mM MgCl2, 2 mM KCN, 15 µM cytochrome 
c, 2 µg/ml of Rotenone, 0.6 mM Dodecyl-β-d-
maltoside; diluted in K buffer 
Complex IV assay buffer 10 mM Tris-HCl (pH 7.0), 120 mM KCl 
Complex IV enzyme dilution buffer 10 mM Tris-HCl (pH 7.0), 250 mM sucrose 
DNA loading buffer (6X)  40% glycerol, 0.25% Bromophenol Blue 
LB-Amp media 1000X Ampicillin in LB broth 
LB-Kan media 1000X Kanomycin in LB broth 
LB plate 1.5% agar in LB media containing antibiotics 
Milk buffer 5% non-fat dry milk, TBS 
Mitochondrial isolation buffer 225 mM D-mannitol, 75 mM sucrose, 2 mM 
K2HPO4 
Phosphate buffered saline (PBS, 10X) 1.37 M NaCl, 27 mM KCl, 20 mM KH2PO4, 
100 mM Na2HPO4, pH 7.4 
Polyacrylamide gel separating buffer 3 M Tris-HCl, pH 8.8 
Polyacrylamide gel stacking buffer 0.5 M Tris-HCl, pH 6.8 
Potassium buffer (25 mM) 3 M KCl, 1 M Tris-HCl, pH 7.4, 0.5 M EDTA 
SDS-PAGE running buffer (10X) 0.25 M Tris, 1.92 M Glycine, 1% SDS, pH 8.0 
SDS-PAGE sample buffer (4X) 150 mM Tris-HCl (pH 6.8), 6% SDS, 0.3% 
Bromophenol Blue, 30% glycerol, 300 mM 
DTT 
Super optimal broth with catabolite repression 
(SOC) media 
2% Tryptone, 0.5% Yeast extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2 
Tris-buffered saline (TBS, 1X) 1 M Tris-HCl (pH 7.4), 5 M NaCl 
TE buffer 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
Western blot transfer buffer (10X) 0.25 M Tris, 1.92 M Glycine, 20% MeOH, pH 
8.3 




Animal weighing scale Kent Scientific Corporation 
Autoclave Service-Rite Medical, Inc. 
Autoflow IR water-jacketed CO2 incubator NuAire 
Branson Sonifier 250 Emerson Industrial Automation 
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Equipment Source 
Caliper Staples Inc. 
Cell culture dishes; 6, 12, 24, and 96 well and 
60, 100, 150 mm dish 
Corning, Thermo Fisher Scientific 
Cell culture flasks; 75 cm
2
 and 25 cm
2
 Nunc 
Confocal microscope Leica Microsystems 
Conical tubes; 15 and 50 ml Thermo Fisher Scientific 
FluorChem HD2 imager Protein Simple 
GeneAmp PCR system 9700 Applied Biosystems 
Hemocytometer VWR 
Hypoxia chamber Coy Laboratories 
Ice machine Hoshizaki America, Inc. 
Inverted microscope Nikon Instruments, Inc. 
In-Vivo Multispectral FX PRO imager Carestream 
LMax II 384 Microplate Reader and SoftMax 
Pro 
Molecular Devices 
Microcentifuge tubes; 0.5, 1.0, and 2.0 ml MidSci 
NanoDrop 1000 spectrophotometer Thermo Fisher Scientific 
Needles, 22-gauge Becton Dickinson 
Pipettes AlphaPette, Rainin 
Pipette tips MidSci 
Precision Trochar Innovative Research of America 
Purified biological safety cabinet tissue culture 
hood 
Labconco 
Sorvall RC 5C plus Thermo Fisher Scientific 
Synergy HT Multi-Mode Microplate Reader BioTek Instruments 
Syringe, 1 ml Becton Dickinson 
Tabletop centrifuge 5417R Eppendorf 
Tabletop centrifuge 5418 Eppendorf 
Ultrospec 3100 pro spectrophotometer Amersham Biosciences 
XF96 extracellular flux analyzer Seahorse Bioscience 
Table 4: List of equipment used in this study 
 
Assay Kits 
Assay Kit Source 
ATP Bioluminescence Assay Kit HS II Roche  
Bicinchoninic Acid (BCA) Protein Assay Pierce  
cDNA High Capacity Reverse Transcription Kit Thermo Fisher Scientific 
CellTiter 96 Non-Radioactive Cell Proliferation 
Assay 
Promega  
In Situ Cell Death Detection Kit, Fluorescein Roche 
Power SYBR Green RT-PCR Reagents Kit Thermo Fisher Scientific 
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Assay Kit Source 
Qiaex II Agarose Gel Extraction Qiagen 
Qiagen Plasmid Mini Kit Qiagen 
Qiagen Plasmid Midi Kit Qiagen 
Qiagen Plasmid Maxi Kit Qiagen 
QiaQuick PCR Purification Kit Qiagen 
Super Signal West Pico Chemiluminescent 
Substrate 
Thermo Fisher Scientific  
Table 5: List of assay kits used in this study 
 
Enzymes, Antibodies, and Markers 
Enzyme, Antibody, or Marker Source 
Alexa Fluor 488 anti-rabbit Invitrogen 
Alexa Fluor 594 anti-mouse Invitrogen 
Anti-β-actin (mouse) Sigma-Aldrich 
Anti-HSD10 (mouse) Yan laboratory 
Anti-HSD10 (rabbit) Yan laboratory 
Anti-COX4/Complex IV Subunit IV  
(mouse) 
Invitrogen 
Anti-CypD (mouse) Abcam 
Anti-CypD (rabbit) Yan laboratory 
Anti-Hsp60 (mouse) Enzo Life Sciences 
Anti-NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 5  
(rabbit, complex I) 
Thermo Fisher Scientific 
Anti-SDHB (rabbit, complex II) Thermo Fisher Scientific 
Anti-SODII (rabbit) Enzo Life Sciences 
Anti-UQCRC2 (rabbit, complex III) Thermo Fisher Scientific 
Multiscribe Reverse Transcriptase Roche 
O’GeneRuler 100bp DNA ladder Thermo Fisher Scientific 
Pierce Protein A/G Sepharose beads Thermo Fisher Scientific 
Quick T4 DNA Ligase Roche 
Trypsin/EDTA Gibco Invitrogen 







The following oligonucleotides were purchased from Sigma-Aldrich, unless stated otherwise. 
Oligonucleotide Target sequence 5’         3’ 
HSD17B10 MISSION® shRNA bacterial 
glycerol stock, human 
TRCN0000318937 
Clone ID: SHCLNG-NM_004493.2-352s21c1 
HSD10 shRNA 1 
ccgggacccataccttggaagacttctcgagaagtcttccaaggt
atgggtctttttg 
HSD17B10 MISSION® shRNA bacterial 
glycerol stock, human 
TRCN0000318935 
Clone ID: SHCLNG-NM_004493.2-189s21c1 
HSD10 shRNA 2 
ccggagttaggaaacaactgcgtttctcgagaaacgcagttgttt
cctaacttttttg 
HSD17B10 MISSION® shRNA bacterial 
glycerol stock, human 
TRCN0000318938 
Clone ID: SHCLNG-NM_004493.2-751s21c1 
HSD10 shRNA 3 
ccggcatcgagaacccattcctcaactcgagttgaggaatgggtt
ctcgatgtttttg 
HSD17B10 MISSION® shRNA bacterial 
glycerol stock, human 
TRCN0000318872 
Clone ID: SHCLNG-NM_004493.2-320s21c1 
HSD10 shRNA 4 
ccgggctagcaagacgtacaacttactcgagtaagttgtacgtctt
gctagctttttg 
ON-TARGETplus Non-targeting Pool 
Human, mouse, and rat 




(3) ugguuuacauguuuucuga  
(4) ugguuuacauguuuuccua 
Peptidylprolyl Isomerase F (PPIF) Silencer 
Human, siRNA ID: 107808 





Table 7: shRNA and siRNA oligonucleotides used for HSD10 and CypD knockdown in rat 
and human cancer cell lines 
 
The following primers were ordered from Sigma-Aldrich. 
Primer Organism Forward Primer 
Sequence 5’       3’ 
Reverse Primer 
Sequence 5’       3’ 
HSD10 Human ctgtcaactgtgcaggcatc ttgaaggtgcccatgagatt 
GAPDH Human atgttcgtcatgggtgtgaa ggtgctaagcagttggtggt 




CSCW-IRES-GFP ShiDu Yan 
CSCW-HSD10-IRES-GFP ShiDu Yan 
pcDNA3  ShiDu Yan 
pcDNA3/(human) wild-type HSD10 ShiDu Yan 
MISSION® TRC2 pLKO.5-puro non-
mammalian shRNA control plasmid DNA 
Sigma-Aldrich 
Table 9: Plasmids used for expression of HSD10 in rat and human cancer cell lines 
 
Bacteria 
E.coli XL1 chemocompetent. 
 
Cell Lines 
Cell Line Source 
Human breast carcinoma (MCF7) ATCC 
Human breast (MCF10A) Liang Xu 
Human breast carcinoma (MDA-MB-231) Liang Xu 
Human breast carcinoma (T47D) Liang Xu 
Human embryonic kidney (HEK-293T) ATCC 
Rat pheochromocytoma (PC-12) ShiDu Yan 
Table 10: List of cell lines used in this study 
 
Animals 
Severe combined immunodeficient (SCID) mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). All animals were housed under pathogen-free conditions 
according to AAALAC guidelines. All animal-related experiments were performed in full 
compliance with institutional guidelines and approved by the Animal Care and Use Committee 





AlphaView 3.2.2.0 Cell Biosciences 
Carestream Molecular Imaging Carestream 
EndNote X6 EndNote 
GraphPad QuickCalcs GraphPad 
ImageJ National Institutes of Health 
Microsoft Office Microsoft 
StateView 5.0.1 SAS Institute 




















The following sections describe the experiments used throughout this dissertation 
pertaining to molecular biology, protein biochemistry, cell culture, mitochondrial function, 




The pcDNA3 plasmid vector (Fig. B-A, Table 9) was used for insertion of the full length 
human HSD10 sequence, as previously described (141). The restriction enzymes Hind III and 
Xho I were used to cut the vector and insert, and were joined together via the ligation reaction 
method described in the following section. The resulting plasmid vector was pcDNA3/(human) 
wild-type HSD10 (Fig. B-B, Table 9). The pcDNA3 vectors were used for stable transfection of 
the PC-12 cells.  
The CSCW-IRES-GFP plasmid vector (Fig. B-C, Table 9) was used for insertion of the 
full length human HSD10 sequence. The restriction enzymes Xba I and Xho I were used to cut 
the vector and insert, and were ligated together. The resultant plasmid vector was CSCW-
(human) wild-type HSD10-IRES-GFP (Fig. B-D, Table 9). The CSCW vectors were used for 








Figure B: Plasmid vector maps used in this study. A. pcDNA3 vector alone was used for the 
stably transfected control PC-12 EV cell line. B. pcDNA3/(human) wild-type HSD10 vector was 
used for the stably transfected HSD10 overexpression PC-12 HSD10 ov cell line. C. CSCW-
IRES-GFP vector alone was used for the lentiviral transfected control MCF10A EV, MCF7 EV, 
and MDA-MB-231 EV cell lines. D. CSCW-HSD10-IRES-GFP vector was used for the 
lentiviral transfected HSD10 overexpression MCF10A HSD10 ov, MCF7 HSD10 ov, and MDA-
MB-231 HSD10 ov cell lines. Adapted from pcDNA3 vector map (153). 
 
Ligation Reaction 
50 ng of vector was combined with a 3-fold molar excess of insert. The volume was 
adjusted to 10 μl with H2O. 10 μl of 2X Quick Ligation Buffer was added, followed by 1 μl of 
Quick T4 DNA Ligase. After thoroughly mixing the solution, the reaction was incubated at room 
temperature (RT) for 5 min. The ligation reaction was kept on ice until the transformation step. 
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Transformation of Bacteria 
Transformation of chemically competent E. coli was achieved by mixing 1 μl of purified 
plasmid DNA (0.1 to 1 ng total) or ligation reaction into 25 μl of competent cells. Samples were 
mixed gently, followed by incubation on ice for 30 min. Bacteria were heat shocked for 30 sec at 
42°C, and then immediately transferred to ice. After the addition of 250 μl of RT SOC media, 
bacteria were incubated at 37°C for 1 hour with shaking. Successively, 50 μl of bacterial culture 
media was spread on a pre-warmed LB agar plate containing the proper antibiotics, and cultured 
overnight at 37°C. 
 
Isolation of DNA (mini, midi, and maxiprep) 
One of the resulting bacterial colonies was picked and cultured in 5 ml LB broth 
containing the proper antibiotics overnight at 37°C with shaking. Plasmid DNA was isolated 
from bacterial with the appropriate kit (Table 5) according to the manufacturer’s instructions. 
Determination of the appropriate kit to use was based on the target amount of isolated plasmid 
DNA: 20 μg for Mini Kit, 100 μg for Midi Kit, and 500 μg for Maxi Kit.  
 
Isolation of RNA 
Total RNA from cancer cells was isolated using 1 ml TRIZOL reagent. Subsequently, 
200 μl of chloroform was added and samples were mixed thoroughly by vigorous shaking. 
Centrifugation for 15 min at 12,000 x g at 4°C separated the upper aqueous phase, which was 
transferred to a new tube. RNA was precipitated by the addition of 500 μl isopropanol and 
incubation at RT for 10 min, followed by centrifugation for 10 min at 12,000 x g at 4°C. The 
pellet was resuspended in 1 ml of 70% EtOH and centrifuged for 5 min at 7,600 x g at 4°C. The 
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resultant pellet was dried in a chemical fume hood for 5-10 min, and then resuspended in a 
suitable volume of water or TE buffer. The concentration of RNA solutions was measured using 
a NanoDrop 1000 spectrophotometer (Table 4). 
 
cDNA Synthesis (reverse transcription) 
RT-PCR (reverse transcription Polymerase Chain Reaction) was performed to convert 
total RNA to single-strand cDNA using the cDNA High Capacity Reverse Transcription Kit 
(Table 5). The RT-PCR reaction was set up in the following 20 μl PCR reaction and the 
subsequent PCR program was used, according to the manufacturer’s instructions. 
 
Materials Volume for One Reaction 
10X RT Buffer 2 μl 
25X dNTP Mix (100 mM) 0.8 μl 
10X RT Random Primers 2 μl 
MultiScribe Reverse Transcriptase 1 μl 
RNase Inhibitor 1 μl 
Nuclease-free H2O 3.2 μl 
RNA sample (1 μg) 10 μl 
Total 20 μl 
Table 12: RT-PCR reaction for the reverse transcription of total RNA 
 
Temperature Time Cycle 
25°C 10 min 1X 
37°C 120 min 1X 
85°C 5 min 1X 
4°C ∞  





Quantitative Real-Time PCR 
To quantify gene expression, qRT-PCR (quantitative real-time PCR) was performed on a 
PCR cycler using the Power SYBR Green RT-PCR Reagents Kit (Table 5). The qRT-PCR 
reaction was set up in the following 50 μl PCR reaction and the subsequent PCR program was 
used, according to the manufacturer’s instructions. The human HSD10 primers used are listed in 
Table 8. 
 
Materials Volume for One Reaction 
Power SYBR Green PCR Master Mix (2X) 25 μl 
Forward Primer (5 μM) 2 μl 
Reverse Primer (5 μM) 2 μl 
cDNA 4 μl 
H2O 17 μl 
Total 50 μl 
Table 14: qRT-PCR reaction for the quantification of total RNA  
 
Temperature Time Cycle 
95°C 10 min 1X 
95°C 15 sec 40X 
60°C 1 min 40X 
4°C ∞  
Table 15: PCR program used for the quantitative amplification of total RNA  
 
CT values measured via qRT-PCR were normalized to GAPDH in human (Table 8). 







Protein Extraction from Cultured Cells 
Adherent cells were washed twice with PBS and then detached in PBS using a scrapper. 
Samples were centrifuged for 5 min at 300 x g at 4°C. The resultant pellet was resuspended in 
PBS containing 100X protease inhibitor cocktail, followed by sonication. Protein concentration 
was measured using the BCA method.  
 
SDS-PAGE 
Continuous SDS-PAGE (polyacrylamide-gel electrophoresis) was performed. Protein 
extracts were boiled with 1 X SDS sample buffer for 10 min at 100°C, followed by separation on 
a 12% separating gel topped with 4% stacking gel alongside stained protein molecular weight 
standards. Gels were run in an electrophoretic chamber at a constant voltage of 100 V until the 
loading dye reached the chamber bottom. A 12% separating gel topped with 4% stacking gel was 
prepared as follows for a standard size SDS gel: 
 
Material 1 separating gel 1 stacking gel 
H2O (RT) 2.1 ml 1.0 ml 
30% bis-acrylamide (4°C) 1.8 ml 220 μl 
Separating buffer (4°C) 560 μl ---- 
Stacking buffer 4°C) ---- 440 μl 
10% SDS (RT) 45 μl 18 μl 
15% APS (4°C) 23 μl 9 μl 
TEMED (4°C) 3 μl 2 μl 






Proteins that were separated via SDS-PAGE were transferred to a 0.45 μm nitrocellulose 
membrane (Thermo Fisher Scientific) by wet transfer at constant voltage (110 V, 80 min) in 
Western blot transfer buffer. The membrane was blocked in 5% milk buffer for 1 hour at RT. 
Antibody incubation times were overnight at 4°C for primary, and 1 hour at RT for secondary 
antibodies with three washing steps in TBS at RT before and after both incubation steps.  
Specific protein bands were visualized by chemiluminescence using Super Signal West 
Pico Chemiluminescent Substrate (Table 5) and a FluorChem HD2 image system (Table 4). 
 
Co-Immunoprecipitation of Protein Complexes 
This pull-down method was used to isolate HSD10 together with potential binding 
partners from HSD10-transfected cancer cells, specifically CypD. 
For extract collection, cells were washed twice with PBS and then detached in Co-IP 
collection buffer using scrappers. Samples were lysed by freezing in liquid nitrogen followed by 
thawing in a 37°C water bath. This freeze-thaw method was repeated for a total of 10 cycles, 
followed by brief sonication and 30 min of lysis on ice. Subsequently, samples were centrifuged 
for 5 min at 8000 x g at 4°C. The resulting supernatant protein concentration was measured using 
the BCA method. Samples with 500 μg protein extracts within 500 μl Co-IP buffer were 
incubated overnight with pull-down antibodies while rotating at 4°C. 
The following morning, samples were incubated with 30 μl of Protein A/G Sepharose 
beads for 2-3 hours on a rotator at 4°C. Subsequently, the beads were washed three times with 
Co-IP wash buffer, and finally resuspended in 1X SDS-PAGE sample buffer. Following 
incubation of the samples in boiling water for 10 min, the supernatant was used for SDS-PAGE. 
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Cell Culture Methods 
Cultivation of Cell Lines 
All adherent cell lines (Table 10) used in this study were grown at 37°C in a humidified 
5% CO2 incubator in either DMEM supplemented with 10% FBS and 100X Pen/Strep (HEK-
293T, MCF7, MDA-MB-231, T47D), RPMI-1640 medium supplemented with 10% horse 
serum, 5% FBS, and 100X Pen/Strep (PC-12), or DMEM/F12 supplemented with 5% horse 
serum, 100 μg/ml EGF, 1 mg/ml Hydrocortisone, 1 mg/ml Cholera toxin, 10 mg/ml Insulin, and 
100X Pen/Strep (MCF10A). At 80-90% confluence, cells were subcultured using trypsin/EDTA 
and a split ratio of 1:10 for HEK-293T and PC-12 cells, 1:7 for MCF10A, MDA-MB-231, and 
T47D cells, and 1:3 for MCF7 was used. 
 
Overexpression of HSD10 in Cultured Cells 
Stable transfection of HSD10 was previously performed in PC-12 cells (127). In brief, 
cells (10
5
 cells) were transfected with pcDNA3/(human) wild-type HSD10 or pcDNA3 alone 
(vector) (Table 9), using Lipofectamine 2000 (141). 48 hours after transfection, cells were plated 
at 1:10-1:20 dilution in 100-mm dishes supplemented with 1 mg/ml G418. After 1-2 weeks, 
single clones were isolated, and cells were separated with trypsin, subjected to limiting dilution, 
and replated in medium containing 1 mg/ml G418 for 2-4 weeks. After, cells were maintained in 
the appropriate media supplemented with 1 mg/ml G418 in a humidified 37°C, 5% CO2 
environment. PC-12 pcDNA3-10 (Fig. B, Lane 1) was chosen as the control cell line. PC-12 
HSD10-52 displayed the greatest abundance of HSD10 (Fig. B, Lane 4) and was selected as the 
HSD10-overexpressing cell line used in Chapters 1 and 3 of this dissertation. 
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Figure C: Selection of the PC-12 HSD10 overexpression cell lines. Stably transfected PC-12 
cell lines were examined for protein expression using the rabbit anti-HSD10 antibody (1:3000) 
via immunoblotting. Actin (mouse anti-Actin antibody, 1:8000) was used as the loading control 
and HSD10 expression was normalized to actin. Lanes: 1) pcDNA3-10, 2) pcDNA3-16, 3) 
HSD10-4, 4) HSD10-52, 5) HSD10-79, 6) HSD10-82. 
 
Due to time constraints, lentiviral transfection was performed in MCF7, MCF10A, and 
MDA-MB-231 cells for the experiments detailed in Chapter 2. HEK 293T cells (2.5 x 10
5
 
cells/well of a 6-well plate) were transfected with CSCW-HSD10-IRES-GFP (green fluorescent 
protein) or CSCW-IRES-GFP (Table 9) using Lipofectamine 2000 and Lentiviral Packaging 
Mix. Cell media was harvested at 36 and 72 hours post-transfection. MCF7, MCF10A, and 
MDA-MB-231 cells (10
5
 cells/well of a 12-well plate) were infected with HSD10 overexpression 
and control media over 10 days with continual passaging. After, the cells were maintained in the 
appropriate media in a humidified 37°C, 5% CO2 incubator, with viral media added to cell 
cultures twice weekly. 
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Knockdown of HSD10 in Cultured Cells 
HEK-293T cells (2.5 x 10
5
 cells/well of a 6-well plate) were transfected with HSD10 
shRNA (Table 7) or non-mammalian control shRNA (Table 9) using Lipofectamine 2000 and 
Lentiviral Packaging Mix. Cell media was harvested at 36 and 72 hours post-transfection. 
HSD10 shRNA 3 demonstrated the largest reduction in HSD10 (Fig. C, Lane 4), and was 
selected as the HSD10 shRNA construct used for all of the HSD10 knockdown studies in this 
dissertation, along with the non-target control shRNA (Fig. C, Lane 1). PC-12 and T47D cells 
(10
5
 cells/well of a 12-well plate) were infected with HSD10 shRNA 3 and control shRNA 
media over 10 days with continual passaging, and then were maintained in the appropriate media 
in a humidified 37°C, 5% CO2 incubator, with viral media added to cell cultures twice a week. 
 
 
Figure D: Selection of the HSD10 shRNA construct. HEK 293T cells were transfected with 
four HSD10 shRNA constructs (Sigma-Aldrich) and harvested for detection of protein 
expression using the rabbit anti-HSD10 antibody (1:3000) via immunoblotting. Actin (mouse 
anti-Actin antibody, 1:8000) was used as the loading control and HSD10 expression was 
normalized to actin. Lanes: 1) non-target control shRNA, 2) HSD10 shRNA 1, 3) HSD10 
shRNA 2, 4) HSD10 shRNA 3, 5) HSD10 shRNA 4. 
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Knockdown of CypD in PC-12 HSD10 ov Cultured Cells 
PC-12 HSD10 overexpression (HSD10 ov) cells (2.5 x 10
5
 cells/well of a 6-well plate) 
were transiently transfected with CypD siRNA (Table 7) or ON-TARGETplus non-targeting 
pool control siRNA (Table 7) using Lipofectamine RNAiMAX. Cells were harvested for 
experimental use 48 hours post-transfection. 
 
Immunofluorescence Staining of Cultured Cells 
Cells (2 x 10
4
 cells/well) were grown in 8-well chamber slides until 70% confluent, and 
then incubated with 100 nM Mito Tracker Red for 30 min, followed by fixation in 4% 
paraformaldehyde and 0.1% Triton X-100 for 30 min. Fixed cells were incubated with rabbit 
anti-HSD10 (1:300) at 4°C overnight. Secondary antibody (Alexa Fluor 488 anti-rabbit, 1:2000) 
was applied to the cells followed by confocal microscopy (Table 4). The intensity of 
fluorescence (ex: 581 nm, em: 644 nm for Mito Tracker Red; ex: 499 nm, em: 520 nm for 
HSD10) was recorded to determine HSD10 expression and mitochondrial localization. 
 
Co-Immunofluorescence Staining of Cultured Cells 
 Cells (2 x 10
4
 cells/well) were grown in 8-well chamber slides until 70% confluent, and 
then fixed in 4% paraformaldehyde and 0.1% Triton X-100 for 30 min. Fixed cells were 
incubated with mouse anti-HSD10 (1:100) and rabbit anti-CypD (1:200), mouse anti-HSD10 
(1:100) and rabbit anti-SODII (1:1000), or mouse anti-Hsp60 (1:1000) and rabbit anti-CypD 
(1:200) overnight, and then incubated with secondary antibodies (Alexa Fluor 488 anti-rabbit 
and Alexa Fluor 594 anti-mouse; 1:2000). DAPI was applied to the cells for 5 min followed by 
confocal microscopy. The intensity of fluorescence (ex: 499 nm, em: 520 nm for HSD10; ex: 
44 
343 nm, em: 442 nm for CypD; ex: 494 nm, em: 518 nm for SODII; ex: 495 nm, em: 519 nm for 
Hsp60; ex: 358 nm, em: 461 nm for DAPI) was recorded to determine HSD10 and CypD 
expression and localization to the mitochondrial markers, SODII and Hsp60.  
 
TUNEL Staining of Cultured Cells 
 The In Situ Cell Death Detection Kit, Fluorescein (Table 5) was used as described. Cells 
(2 x 10
4
 cells/well) were grown in 8-well chamber slides until 70% confluent. Following 
incubation for 24 hours with 0.75 mM H2O2, the cells were fixed in 4% paraformaldehyde for 1 
hour. Fixed cells were permeabilisated for 2 min on ice, followed by incubation with 75 μl 
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) reaction mixture for 1 
hour at 37°C. After washing twice with PBS followed by 5 min of nuclear staining with DAPI, 
the cells were imaged via confocal microscopy and the intensity of fluorescence (ex: 488 nm, 
em: 565 nm for TUNEL; ex: 358 nm, em: 461 nm for DAPI) was recorded to determine cells 
undergoing apoptotic cell death. 
 
Cell Growth Curve Analysis 
Cells were plated in 7-10 100-mm dishes at a density of 1-2.5 x 10
5
 cells/dish, depending 
on the cell type. One dish was chosen each consecutive day to be counted. The cells in the dish 
were detached with trypsin/EDTA, centrifuged, and resuspended in 1 ml of media, followed by 





Mitochondrial Function Assays 
Mitochondrial Membrane Staining of Cultured Cells 
Cells (2 x 10
4
 cells/well) were grown in 8-well chamber slides until 70% confluent, and 
then incubated with 150 nM Mito Tracker Green and 100 nM TMRM (non-quench mode) for 30 
min, followed by washing twice with HBSS media. Cells were imaged live by confocal 
microscopy and the intensity of fluorescence (ex: 490 nm, em: 516 nm for Mito Tracker Green; 
ex: 490 nm, em: 550 nm for TMRM) was recorded to determine the uncollapsed proton gradient. 
 
MTT Reduction 
The CellTiter 96 Non-Radioactive Cell Proliferation kit (Table 5) was used to measure 
metabolic activity. Cells (10
4 
cells/well) were plated in 96-well plates 48 hours prior to the 
experiment. For cellular resistance experiments, H2O2 (0.1, 0.25, 0.5, 0.75, and 1 mM) and TBH 
(0.1 and 0.25 mM) were added to cells 24 hours prior to incubation with 15 μl/well of MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye solution for 4 hours. 
Successively, 100 μl/well of solubilization solution was added to stop the reaction, and then the 
plates were incubated for 1 hour. The change in absorbance at 570 nm was recorded using a 96-
well Synergy HT Multi-Mode Microplate Reader (Table 4). A reference wavelength of 650 nm 
was taken to reduce background. 
 
ATP Activity 
Cellular ATP levels were measured using the Bioluminescence Assay Kit HS II (Table 
5) following the manufacturer’s instructions as previously described (154). Briefly, cells (30 x 
10
4
 cells/well) were grown in 6-well plates until fully confluent. Cells were washed twice with 
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ice-cold PBS, followed by the addition of 50 µl/well of ATP Lysis Buffer. Samples were 
harvested, incubated on ice for 20 minutes, and then centrifuged. Protein content of the 
supernatant was determined using the BCA method. Proportional amounts of sample were added 
to a 96-well ATP plate (25 µl/well). The reaction solution was brought to 50 µl/well with the 
addition of ATP Dilution Buffer. ATP levels were determined using an LMax II 384 Microplate 
Reader and SoftMax Pro (Table 4). 
 
ETC Enzyme Activity 
Briefly, cells (10
6
 cells/dish) were grown in 150-mm dishes until fully confluent. For 
measurement of complex IV enzymatic activity in response to oxidative stress, 750 μM of H2O2 
was added to cells and incubated for 1, 6, 16, and 24 hours before collection. Cells were washed 
twice with pre-chilled PBS, and then harvested, centrifuged, and suspended in 100 µl of 
mitochondrial isolation buffer. A working solution of 25 mM K buffer was used for complex I, 
II, III, and IV assays as described (154). An Ultrospec 3100 pro spectrophotometer (Table 4) 
was used to measure the change in absorbance for all complexes. Background levels were 
measured in the absence of cell suspensions. All complex enzyme activities are expressed as 






1 (nmol/mg protein/min/ml) 
converted to fold increase. 
a. Complex I 
Cell lysate (30-50 µg of protein/ml) was added to a cuvette containing 0.5 ml of 
Complex I reaction buffer. The reaction was started by the addition of Coenzyme Q1 (2 
μl of 65 µM solution). At 180 sec, 2 µl of Rotenone (2 µg/ml) was added to the cuvette. 
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The change in absorbance at 340 nm, resulting from the oxidation of NADH, was 
measured using a kinetic program with 20 sec intervals and a total of 18 readings. 
b. Complex II 
Cell suspensions (30-50 µg of protein/ml) were added to a 1.5 ml microcentrifuge tube 
containing 0.5 ml of Complex II reaction solution 1, and then incubated in a 37°C water 
bath for 10 minutes. After transferring the cell solution to a cuvette, the reaction was 
started by the addition of 8 µl of Complex II reaction solution 2. At 180 sec, 2 µl of 
Coenzyme Q2 (65 µM) was added to the cuvette. The change in absorbance at 600 nm, 
resulting from the reduction of DCPIP, was measured using a kinetic program with 20 
sec intervals and a total of 18 readings. 
c. Complex III 
The reaction was started by the addition of 2 µl of Coenzyme Q2 (65 µM) to a cuvette 
containing 0.5 ml of Complex III reaction buffer. At 60 sec, a cell suspension (30-500 
µg of protein/ml) was added to the cuvette. The change in absorbance at 550 nm, 
resulting from the reduction of cytochrome c, was measured using a kinetic program 
with 20 sec intervals and a total of 12 readings. 
d. Complex IV 
Cell lysate (30 µg of protein/ml) was added to a cuvette containing 0.475 ml of 
Complex IV assay buffer, and the reaction volume was brought to 0.525 ml with 
Complex IV enzyme dilution buffer. The reaction was started by the addition of 25 µl 
of ferrocytochrome c substrate solution (0.22 mM). The change in absorbance at 550 
nm, resulting from the oxidation of cytochrome c, was measured using a kinetic 
program with a 5 sec delay, 10 sec intervals, and a total of 6 readings.  
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Citrate Synthase Enzyme Activity 
Cells in 100-mm dishes were washed twice with cold PBS, and cells were harvested, 
centrifuged, and suspended in 100 µl of mitochondrial isolation buffer. The reaction was started 
by the addition of cell lysate (10-30 µg of protein/ml) to a cuvette containing 150 µl of citrate 
synthase assay buffer. The change in absorbance at 232 nm was measured using a kinetic 




















Maintenance of Mouse Lines 
Two-month old SCID mice were purchased from Jackson Laboratories and continuously 
bred on the Yan breeding protocol to acquire SCID mouse generations for experimental use.  
 
Injection of Cultured Cells into Mice 
HSD10-transfected cancer cells were grown in 150-mm dishes until fully confluent, 
followed by suspension in serum free cell culture medium. Single injections containing 1-5 x 10
6
 
cells per 100 μl medium were prepared under a sterile tissue culture hood. Cancer cells were 
injected into the mammary fat pad tissue of female SCID mice using the following protocol. 
Following anesthesia with 2% isofluorane, the mammary gland area was shaved and sterilized 
with alcohol. Two injections of HSD10-transfected cancer cells were made using a sterile 22-
gauge needle with manual restraint (155), one injection per fifth mammary fat pad area on each 
side of the mouse. 
 
Imaging and Measurement of Tumor Growth 
Tumor-inoculated mice were weighed and tumor size was measured using a caliper twice 
per week for a total of 30 days. Tumor volume was calculated using the formula: (length x 
width
2
)/2 (156). Mice were imaged with an In-Vivo Multispectral FX PRO imaging system 
(Table 4) on day 30 of the experiment, 24 hours post-injection of 15 nmol 2-DG optical probe 
(Table 2) (157) given via tail vein injection. An excitation filter of 760 nm and emission filter of 




Paired t tests were used for statistical comparison of empty vector (EV) with HSD10 ov 
groups, control shRNA with HSD10 shRNA groups, and control siRNA with CypD siRNA 
groups. Unpaired t tests were used to analyze all animal data. Concerning the TUNEL staining 
assays, one-way analysis of variance was used for statistical comparison between groups, with 
the post-hoc tests Bonferroni/Dunn and Tukey-Kramer performed after. All data was analyzed 
using the software described in Table 11, and results are reported as mean ± SE. P<0.05 was 




















Chapter 1: Impact of HSD10 on Altered Pheochromocytoma Cells 
 
The rat adrenal gland cancer cell line, PC-12, was used to examine the role of HSD10 in 
cancer progression. PC-12 cell growth rate was first observed in the HSD10-transfected cells to 
determine if HSD10 influences PC-12 cell differentiation in cell culture. Subsequently, the effect 
of HSD10 on tumor growth was examined using an in vivo tumor mouse model. After observing 
differing growth patterns in PC-12 cells due to overexpression and knockdown of HSD10, 
mitochondrial functions were assessed to investigate the impact of HSD10 on intracellular 
function. The role of HSD10 in PC-12 cellular resistance to cell death was also examined. 
Finally, the interaction between HSD10 and CypD was investigated as a possible mechanism of 












1.1. Generation of HSD10-transfected Pheochromocytoma Cell Lines 
Following transfection, PC-12 cancer cells expressing either an empty pcDNA3 vector or 
an HSD10 ov vector (Table 9) were subjected to immunoblotting for analysis of protein content. 
HSD10 protein expression was increased by over 2.5-fold in HSD10 ov cells compared to EV 
cells (Fig. 1-1 A). To thoroughly examine the effect of HSD10 in cancer, lentiviral transfection 
using a shRNA oligonucleotide (Table 7) was used to knockdown HSD10 in PC-12 cells. 
Immunoblot analysis revealed that HSD10 protein expression was significantly reduced by 80% 
in HSD10 shRNA-transfected cells in comparison with control shRNA-transfected cells (Fig. 1-1 




Figure 1-1: Generation of PC-12 HSD10-transfected cells. PC-12 transfected cells were 
harvested for detection of protein expression using rabbit anti-HSD10 antibody (1:3000, 
generated in the Yan lab) via immunoblotting. Actin (mouse anti-Actin antibody, 1:8000) was 
used as the protein loading control and HSD10 expression was normalized to actin. Results are 
displayed as fold increase relative to EV (A) or control shRNA (B). A. EV and HSD10 ov whole 
cell lysates were analyzed for HSD10 protein expression (n=4). B. Control shRNA and HSD10 
shRNA whole cell lysates were analyzed for HSD10 protein expression (n=4). Data presented as 
mean ± SE. *P<0.05, **P<0.01 versus control group. Adapted from Carlson, E.A. et al. (2015) 
BMC Cancer (152). 
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1.2. Localization of HSD10 in HSD10-transfected Pheochromocytoma Cells 
At the N-terminus, HSD10 contains a mitochondrial targeting sequence (111), which was 
shown to direct HSD10 to mitochondria in human neuroblastoma cells (141). To further confirm 
HSD10 transfection success and to investigate whether upregulation and/or downregulation of 
HSD10 interferes with the enzyme’s normal localization pattern, HSD10 in PC-12 cells was co-
stained with the mitochondrial dye Mito Tracker Red (Fig. 1-2). 
The intensity of HSD10 staining was significantly enhanced in HSD10 ov cells in 
comparison with EV cells (Fig. 1-2 A-B). In addition to confirming increased levels of HSD10 
in the PC-12 HSD10 ov cells, the immunofluorescence assay established the localization of 
HSD10 to mitochondria, as depicted in the merged picture of Figure 1-2 A. The level of HSD10 
knockdown was also confirmed by immunofluorescence staining of HSD10 (Fig. 1-2 C), which 
revealed that the intensity of HSD10 staining was decreased in HSD10 shRNA cells compared to 
control shRNA cells (Fig. 1-2 D).  
Thus, HSD10 upregulation does not seem to interfere with the enzyme’s normal 
localization pattern to mitochondria. Similarly, HSD10 downregulation does not appear to 
disrupt mitochondrial localization; there was less co-staining with Mito Tracker Red, however 









Figure 1-2: Localization of HSD10 in PC-12 HSD10-transfected cells. PC-12 transfected cells 
were cultivated on chamber slides and proteins were detected using rabbit anti-HSD10 antibody 
(1:300) and Mito Tracker Red (1:500). After incubation with anti-rabbit Alexa Fluor 488 
(1:500), cells were mounted in fluorescence mounting media. Confocal microscopy was used to 
visualize immuno-fluorescence staining of A. HSD10 alone (green), Mito Tracker Red alone 
(red), and these two antigens co-localized (yellow) in EV and HSD10 ov PC-12 cells (scale bar: 
30 μm). B. Quantification of HSD10 immunofluorescence staining (depicted in A) displayed as 
fold increase relative to EV (n=5). C. Immunofluorescence staining of HSD10 alone (green), 
Mito Tracker Red alone (red), and merged (yellow) in control shRNA and HSD10 shRNA PC-12 
cells (scale bar: 30 μm). D. Quantification of HSD10 immunofluorescence staining (depicted in 
C) displayed as fold increase relative to control shRNA (n=5). Data presented as mean ± SE. 
*P<0.05, **P<0.01 versus control group. Adapted from Carlson, E.A. et al. (2015) BMC Cancer 
(152). 
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1.3. In Vitro HSD10-transfected Pheochromocytoma Cell Growth Curve Analysis 
The effect of HSD10 modification on PC-12 cell growth was examined using in vitro cell 
culture. PC-12 HSD10-overexpression and PC-12 HSD10-knockdown cell lines were plated in 
dishes at a constant density and grown over the course of seven days, with a dish counted each 
day. As shown in Figure 1-3 A, HSD10 ov cells grew at a significantly faster rate compared to 
EV cells over the seven days. In contrast, knockdown of HSD10 led to a considerable decrease in 
growth rate compared with control shRNA cells (Fig. 1-3 B). Taken together, these results 
suggest that HSD10 promotes pheochromocytoma cell growth in cell culture and that 
knockdown of HSD10 has a negative effect on cancer cell growth.  
 
 
Figure 1-3: Effect of HSD10-modification on in vitro PC-12 cell growth. PC-12 transfected 
cells plated at a constant density were grown and counted over the course of 7 days to determine 
cell growth rate. A. Growth curve of EV (white ■) and HSD10 ov (black ■) cells displayed as 
cells x 10
4
 per ml (n=9). B. Growth curve of control shRNA (light gray ■) and HSD10 shRNA 
(dark gray ■) cells depicted as cells x 10
4
 per ml (n=9). Data presented as mean ± SE. *P<0.05, 




1.4. In Vivo HSD10-transfected Pheochromocytoma Tumor Growth Analysis 
After observing an enhancement in PC-12 cell growth rate in HSD10 ov cells compared 
to EV cells, a xenograft tumor mouse model was used in a study to validate the role of HSD10 
on PC-12 cancer cell growth in vivo. SCID mice inoculated with HSD10 ov cells exhibited 
drastically larger tumors compared to mice with EV tumor xenografts which displayed very 
minimal growth (Fig. 1-4 A). Furthermore, HSD10 ov tumors grew at a significantly faster rate 
over 32 days compared to EV tumors (Fig. 1-4 B). These results demonstrate that HSD10 
overexpression accelerates tumor development in vivo, providing further evidence that HSD10 is 
an important cancer mediator in adrenal gland cancer.  
While there are limited in vivo xenograft studies involving PC-12 cells, one group 
revealed that following implantation of PC-12 cells into the striatum of Sprague-Dawley rats, the 
number of cells remained unchanged and there was no continued tumor growth (158). This study 
corroborates the minimal growth observed in the EV tumors (Fig. 1-4) and provides further 











Figure 1-4: HSD10 overexpression enhances in vivo PC-12 tumor growth. PC-12 transfected 
EV and HSD10 ov cells were injected into the mammary fat pad tissue of 10 two-month old 
female SCID mice. A. Day 30 tumor growth in two SCID mice inoculated with EV (left mouse) 
or HSD10 ov (right mouse) cells was visualized 24 hours post-injection of 15 nmol 2-DG optical 
dye with an In-Vivo Multispectral FX PRO imager. Arrows point to tumors. B. Quantification of 
tumor growth in all SCID mice injected with EV (n=8; white ■) or HSD10 ov (n=12; black ■) 
cells grown over a total of 32 days, depicted in tumor volume (mm
3
). Data presented as mean. 











1.5. Effect on Altered Pheochromocytoma Mitochondrial Function 
Following the successful studies evaluating HSD10-mediated PC-12 cancer growth, the 
effect of HSD10 on intracellular mitochondrial function was examined for changes in processes. 
The enzyme activities of complexes I, II, III, and IV of the ETC were tested first to investigate 
the impact of HSD10 alteration on mitochondrial respiration.  
While the enzyme activities of complexes I, II, and III remained unchanged (Fig. 1-5 A-
C), complex IV activity was significantly increased in HSD10 ov cells compared with EV cells 
(Fig. 1-5 D), suggesting an enhancement in the ETC system of HSD10-overexpressing PC-12 
cells. Conversely, HSD10 shRNA cells displayed significantly decreased ETC complex enzyme 
activity in all of the complexes measured, in comparison to control shRNA cells (Fig. 1-5 A-D). 
This reduction in all of the complexes indicates that HSD10 is important for PC-12 cancer cell 




Figure 1-5: Examination of ETC enzyme activities in PC-12 HSD10-transfected cells. PC-12 
transfected cells were harvested and tested for ETC complex I (A), II (B), III (C), and IV (D) 
enzyme activities. Results are displayed as fold increase relative to EV for HSD10 ov, and 
control shRNA for HSD10 shRNA (n=5 for each assay). Data presented as mean ± SE. *P<0.05, 
**P<0.01 versus EV and control shRNA groups. Adapted from Carlson, E.A. et al. (2015) BMC 
Cancer (152). 
  
The changes seen in the ETC complex enzyme activities for the HSD10-overexpression 
cell lines were not accompanied by variations in ETC complex protein expression (Fig. 1-6 A-
D). However, the HSD10-knockdown cells showed a trend toward reduced ETC complex protein 
expression (Fig. 1-6 E-H); although the only statistically significant difference was observed in 
complex II of the HSD10 shRNA cells (Fig. 1-6 F). This implies that loss of HSD10 impacts 
both ETC complex protein content and enzyme activity. 
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Figure 1-6: Effect of HSD10-modification on PC-12 ETC complex protein expression. PC-
12 EV and HSD10 ov cells were harvested for detection of complex I (A), II (B), III (C), and IV 
(D) protein expression via immunoblotting with the appropriate antibodies listed in Table 6. PC-
12 control shRNA and HSD10 shRNA cells were harvested for detection of complex I (E), II 
(F), III (G), and IV (H) protein expression via immunoblotting with the appropriate antibodies. 
Actin (mouse anti-Actin antibody, 1:4000) was used as the loading control and each complex 
protein expression was normalized to actin (n=4 for each group). Data presented as mean ± SE. 
*P<0.05 versus control shRNA group. 
 
As complex IV enzyme activity was enhanced in PC-12 HSD10 ov cells, the impact of 
this change on ATP production was assessed. ETC complexes I, III, and IV are proton pumps, 
which generate the transmembrane proton gradient necessary to drive ATP generation by ATP 
synthase. Thus, changes in the ETC system would impact mitochondrial ATP generation and any 
ensuing mitochondrial processes.  
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In conjunction with the complex IV data observed in Figure 1-5 D, the level of ATP was 
significantly elevated in HSD10 ov cells compared to EV cells (Fig. 1-7), demonstrating a 
possible increase in energy generation in HSD10-overexpressing PC-12 cells. On the other hand, 
ATP production was diminished in HSD10 shRNA cells compared to control shRNA cells (Fig. 
1-7), which was expected in view of the decreased activity and protein content observed in all of 
the ETC complexes in Figure 1-5 A-D.   
 
 
Figure 1-7: Assessment of ATP production in PC-12 HSD10-transfected cells. PC-12 
transfected cells were harvested for determination of cellular ATP content. Densitometry of 
results displayed as fold increase relative to EV for HSD10 ov, and control shRNA for HSD10 
shRNA (n=6). Data presented as mean ± SE. *P<0.05, **P<0.01 versus EV and control shRNA 
groups. Adapted from Carlson, E.A. et al. (2015) BMC Cancer (152). 
 
As alterations in several ETC complexes and ATP production were observed in HSD10-
modified PC-12 cells, citrate synthase enzyme activity was assessed as a mitochondrial control; 
it is typically used as a quantitative enzyme marker for the presence of intact mitochondria.  
Citrate synthase enzyme activity was similar between HSD10 ov cells and EV cells (Fig. 
1-8), indicating that, despite an overabundance of HSD10, the PC-12 HSD10-overexpressing 
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cells were healthy. However, citrate synthase enzyme activity, which serves as a measurement of 
mitochondrial fitness, was slightly reduced in HSD10 shRNA cells (Fig. 1-8). This suggests that 
HSD10 knockdown disrupts mitochondrial function and structure. Further investigation into how 
knockdown of HSD10 influences mitochondrial morphology is needed. 
 
 
Figure 1-8: Analysis of citrate synthase enzyme activity in PC-12 HSD10-transfected cells. 
PC-12 transfected cells were harvested and citrate synthase enzyme activity was tested. 
Densitometry of results displayed as fold increase relative to EV for HSD10 ov, and control 
shRNA for HSD10 shRNA (n=5). Data presented as mean ± SE. *P<0.01 versus control shRNA 
group. Adapted from Carlson, E.A. et al. (2015) BMC Cancer (152). 
 
ATP is a key driver for many mitochondrial and cellular processes. As ATP levels in the 
HSD10-transfected PC-12 cells were altered compared to controls, the effect of HSD10 on cell 
viability was measured using the MTT reduction assay which tests cellular metabolic activity 
due to NAD(P)H flux.  
MTT reduction levels remained similar between HSD10 ov cells and EV cells after 24 
hours, indicating comparable cell viability (Fig. 1-9 A). Furthermore, the change in MTT 
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reduction between control shRNA and HSD10 shRNA cells was not statistically significant after 
24 hours (Fig. 1-9 A), although the slight decrease observed in HSD10 shRNA cells 
demonstrates a small trend. The MTT reduction data indicate that the changes observed in the 
ETC complexes and ATP generation is the result of PC-12 cell growth rate. 
The effect of HSD10 on mitochondrial function was further assessed via mitochondrial 
membrane potential using the cell-permeant dye, TMRM. This red dye is readily taken up by 
active mitochondria and emits a stronger fluorescence in mitochondria with intact organelle 
membranes (159). Also, TMRM co-localizes with Mito Tracker Green (Fig. 1-9 B and D).  
HSD10 ov cells displayed enhanced TMRM staining as opposed to the normal levels 
observed in EV cells (Fig. 1-9 B-C). Alternatively, HSD10 shRNA cells displayed a decrease in 
TMRM staining intensity compared to control shRNA cells (Fig. 1-9 D-E). Due to the 
significant increase in TMRM fluorescence observed in HSD10 ov cells, HSD10 overexpression 
may promote mitochondrial membrane hyperpolarization. Whereas loss of mitochondrial 
membrane potential can induce cell death pathways, hyperpolarization mediated in part by 
HSD10 could lead to protection against induction of cell death. In HSD10 shRNA cells, there is 
considerably less HSD10 present within mitochondria; hence HSD10 knockdown may induce 









Figure 1-9: Examination of intact mitochondria in PC-12 HSD10-transfected cells. PC-12 
transfected cells were cultivated on a 96-well plate for an MTT assay and on chamber slides for 
observation of mitochondrial membrane potential.  Following treatment with MTT dye for 4 
hours, cells were assessed for MTT reduction using a multi-plate reader. A. Densitometry of 
MTT reduction displayed as fold increase relative to EV for HSD10 ov, and control shRNA for 
HSD10 shRNA (n=4). After incubation with TMRM (1:300) and Mito Tracker Green (1:500), 
cells were imaged live for membrane potential. B. Confocal microscopy was used to observe 
immunofluorescence staining of mitochondrial membrane potential with TMRM alone (red), 
Mito Tracker Green alone (green), and their co-localization (yellow) in EV and HSD10 ov cells 
(scale bar: 30 μm). C. Quantification of TMRM immunofluorescence staining (depicted in B) 
displayed as fold increase of intensity of fluorescence relative to EV (n=4). D. 
Immunofluorescence staining of TMRM alone (red), Mito Tracker Green alone (green), and 
merged (yellow) in control shRNA and HSD10 shRNA cells (scale bar: 30 μm). E. 
Quantification of TMRM immunofluorescence staining (depicted in D) displayed as fold 
increase of fluorescence intensity relative to control shRNA (n=4). Data presented as mean ± SE. 







1.6. Influence on Altered Pheochromocytoma Cell Resistance 
It is a well-known, discouraging fact that many cancers can become resistant to 
anticancer therapies over time. As this is a major problem for patients, the effect of HSD10 
overexpression on cancer cell resistance to oxidative stress was assessed using the PC-12 cells 
overexpressing HSD10. The cells were treated with various concentrations of H2O2 and TBH for 
24 hours to stimulate oxidative stress conditions, as cancer cells are typically exposed to higher 
oxidative stress levels (45). While cell viability steadily decreased for both groups as the 
chemical dosage increased, HSD10 ov cells demonstrated significantly higher reduction of MTT 
at 0.75 and 1 mM concentrations of H2O2 compared to EV cells (Fig. 1-10 A). Treatment of the 
cells with TBH showed similar results, with HSD10 ov cells reducing considerably more MTT 
compared to EV cells at the lowest dosage of TBH used (0.1 mM, Fig. 1-10 B). Thus, while 
these two oxidative stressors reduce cell viability in both EV and HSD10 ov cells, PC-12 cells 
with HSD10 overexpression exhibited more resistance to chemical-induced oxidative stress.  
This observed cellular resistance was further examined using complex IV enzyme 
activity. PC-12 cells were treated with 0.75 mM of H2O2 as the amount of MTT reduced by EV 
cells remained at a higher level compared to the amount seen at 1 mM H2O2 (Fig. 1-10 A) and 
the lowest dose of TBH given (Fig. 1-10 B). As a starting point, complex IV activity was 
assessed in cells treated with 0.75 mM of H2O2 for 24 hours. However, H2O2 treatment showed 
no difference in enzyme activity between the two PC-12 groups (Fig. 1-10 C). Rationalizing that 
any changes in enzymatic activity would likely be more visible earlier in the chemical treatment, 
the activity of complex IV was assessed at several time points during the 24 hour period. As 
speculated, complex IV enzyme activity was significantly increased in HSD10 ov cells compared 
to EV cells after just one hour of H2O2 treatment (Fig. 1-10 D). Indeed, this difference in activity 
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occurred earlier into the treatment period as the difference between HSD10 ov and EV cells at 16 
hours of H2O2 treatment returned to similar levels (Fig. 1-10 D). This data implies that HSD10 
overexpression aids cell survival under oxidative stress settings, conceivably by elevating and/or 
maintaining mitochondrial bioenergetics, such as ETC activity and ATP generation, during this 
death-inducing condition.  
Additionally, complex IV enzyme activity was used to assess cellular resistance in the 
PC-12 HSD10 knockdown cells treated with 0.75 mM H2O2 for the same time points over 24 
hours. Interestingly, complex IV enzyme activity was significantly decreased in HSD10 shRNA 
cells in comparison to control shRNA cells after just one hour of H2O2 treatment (Fig. 1-10 E). 
The significant difference observed between HSD10 shRNA and control shRNA cells was 
sustained for all other time points during the 24 hour treatment period (Fig. 1-10 E), indicating 




Figure 1-10: Effect of HSD10-modification on PC-12 cellular resistance to oxidative stress. 
A-B. Densitometry of MTT reduction in PC-12 transfected EV and HSD10 ov cells treated with 
A) 0, 0.1, 0.25, 0.5, 0.75, and 1 mM H2O2 (n=3 for all groups), and B) 0, 0.1, and 0.25 mM TBH 
for 24 hours (n=3 for all groups), displayed as fold increase relative to EV and HSD10 ov at the 
0 mM time point. C-D. ETC complex IV enzyme activity was assessed in EV and HSD10 ov 
cells treated with 0.75 mM H2O2 for C) 24 hours (n=3), and D) 0, 1, 6, and 16 hours (n=6 for all 
time points), displayed as fold increase relative to EV at the 0 mM time point. E. ETC complex 
IV enzyme activity was assessed in control shRNA and HSD10 shRNA cells treated with 0.75 
mM H2O2 for 0, 1, 6, 16, and 24 hours (n=4 for all time points), displayed as fold increase 
relative to control shRNA at the 0 mM time point. Data presented as mean ± SE. *P<0.05, 
**P<0.01, ***P<0.001 versus control groups. Adapted from Carlson, E.A. et al. (2015) BMC 
Cancer (152). 
68 
To provide further evidence for this concept, TUNEL staining was performed in the PC-
12 HSD10 modified cell lines after treatment with 0 mM or 0.75 mM H2O2 for 24 hours (Fig. 1-
11 A and C). As expected, both EV and HSD10 ov cells treated with H2O2 exhibited higher 
percentages of cells undergoing apoptosis (Fig. 1-11 B, *p-values), compared with the untreated 
matched control groups. However, the HSD10 ov treatment group had significantly less TUNEL 
staining compared to the EV treatment group (Fig. 1-11 B, #p-value), indicating that cells 
overexpressing HSD10 are more protected from stress-induced apoptosis induction.  
Similarly, control shRNA and HSD10 shRNA cells treated with H2O2 displayed greater 
TUNEL staining (Fig. 1-11 D, *p-values), compared to the untreated matched control groups. 
Interestingly, untreated HSD10 shRNA cells showed higher percentages of cells undergoing 
apoptosis in comparison with untreated control shRNA cells (Fig. 1-11 D, &p-values). This 
implies that knockdown of HSD10 renders cells more vulnerable to apoptosis, even under 
normal conditions. Furthermore, the HSD10 shRNA treatment group had significantly more 
TUNEL staining compared to the control shRNA treatment group (Fig. 1-11 D, ^p-values), 
which suggests that cells lacking HSD10 are more susceptible to stress-induced apoptosis 
induction. 
The data presented here support the concept that HSD10 overexpression increases 
pheochromocytoma cell resistance to cell death induced by oxidative stress, and that HSD10 
knockdown renders the cells more susceptible to apoptosis induction. Together, this suggests that 







Figure 1-11: Assessment oxidative stress-induced cell death in PC-12 HSD10-transfected 
cells. A. Confocal microscopy demonstrating TUNEL staining of cells undergoing apoptosis 
(green), nuclear staining with DAPI (blue), and these two antigens co-localized (merged) in PC-
12 transfected EV and HSD10 ov cells (A), control shRNA and HSD10 shRNA cells (C) treated 
with 0 mM and 0.75 mM H2O2 for 24 hours. Scale bar in A and C: 30 μm. B. Quantification of 
EV and HSD10 ov cell TUNEL staining (depicted in A) displayed as the percentage of TUNEL 
positive cells (n=4). D. Quantification of control shRNA and HSD10 shRNA cell TUNEL 
staining (depicted in C) displayed as the percentage of TUNEL positive cells (n=10). Data 
presented as mean ± SE. *P<0.01 versus EV and HSD10 ov non-treatment groups; **P<0.001 
versus control shRNA non-treatment group; ***P<0.0001 versus HSD10 shRNA non-treatment 
group; #P<0.01 versus EV treatment group; &P<0.01 versus control shRNA non-treatment 
group; ^P<0.05 versus control shRNA treatment group. Adapted from Carlson, E.A. et al. (2015) 


















1.7. Interaction between HSD10 and CypD in Altered Pheochromocytoma Cells 
Next, the mechanism behind the ability of HSD10 to regulate cancer cell growth and cell 
death resistance associated with mitochondrial function was examined. As the hypothesis of this 
dissertation is that HSD10 aids in cancer cell resistance by preventing MPTP-induced cell death 
via enhanced binding to CypD, the relationship between HSD10 and CypD was studied in the 
PC-12 overexpression cell lines.  
Immunoblot analysis revealed that despite the large increase in HSD10 protein (Fig. 1-12 
A), CypD protein expression remained similar between HSD10 ov cells and EV cells (Fig. 1-12 
B); this is consistent with other studies of CypD in cancer (83). Interestingly, the decrease in 
HSD10 protein in HSD10 shRNA cells (Fig. 1-12 C) was paired with a reduction in CypD 
protein expression compared with control shRNA cells (Fig. 1-12 D), although CypD protein 
was still more prevalent than HSD10 protein in the HSD10 shRNA cells. This data indicates that 
while CypD expression remains level during HSD10 overexpression, it is negatively impacted by 
HSD10 reduction. This suggests that, due to the reductions in both HSD10 and CypD, cancer 







Figure 1-12: HSD10 and CypD abundance in PC-12 HSD10-transfected cells. PC-12 
transfected cells were harvested for detection of protein expression using rabbit anti-HSD10 
antibody (1:3000) and mouse anti-CypD antibody (1:8000) via immunoblotting. Actin (mouse 
anti-Actin antibody, 1:8000) was used as the loading control, and HSD10 and CypD expression 
were normalized to actin. A-B. EV and HSD10 ov whole cell lysates were analyzed for HSD10 
(A) and CypD (B) protein expression (n=4). C-D. Control shRNA and HSD10 shRNA whole 
cell lysates were analyzed for HSD10 (C) and CypD (D) protein expression (n=4). Results are 
displayed as fold increase relative to EV for HSD10 ov, and control shRNA for HSD10 shRNA. 
Data presented as mean ± SE. *P<0.05, **P<0.01 versus EV and control shRNA groups. 
Adapted from Carlson, E.A. et al. (2015) BMC Cancer (152). 
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Furthermore, the co-localization of HSD10 and CypD within mitochondria was 
confirmed via co-immunofluorescence in the PC-12 overexpression cell lines (Fig. 1-13 A). The 
expression pattern of CypD did not change between EV and HSD10 ov cells (Fig. 1-13 E), 
which coincides with the CypD protein expression data shown in Figure 1-12 B. As expected, 
HSD10 levels were increased in HSD10 ov cells compared to EV cells (Fig. 1-13 D), consistent 
with the results in Figures 1-1 A and 1-2 B.  
Co-staining of HSD10 and CypD with the mitochondrial markers SODII and Hsp60, 
respectively, verified mitochondrial localization of the proteins (Fig. 1-13 B-C). Although CypD 
expression remained constant between EV and HSD10 ov cells, the increased expression of 
HSD10 in HSD10 ov cells appears to correspond with enhanced co-localization of HSD10 and 
CypD as shown in the merged images of Figure 1-13 A. This co-localization positions both 











Figure 1-13: Localization of CypD in PC-12 HSD10-overexpression cells. PC-12 transfected 
cells were cultivated on chamber slides and proteins were detected using mouse anti-HSD10 
(1:100) and rabbit anti-CypD (1:200), mouse anti-HSD10 (1:100) and rabbit anti-SODII 
(1:1000), or mouse anti-Hsp60 (1:1000) and rabbit anti-CypD (1:200). After incubation with 
anti-mouse Alexa Fluor 594 (1:2000) and anti-rabbit Alexa Fluor 488 (1:2000), cells were 
mounted in fluorescence mounting media. Confocal microscopy was used to visualize immuno-
fluorescence staining of A. HSD10 alone (red), CypD alone (green), and these two antigens co-
localized (yellow) with DAPI nuclear staining (blue) in EV and HSD10 ov PC-12 cells (scale 
bar: 20 μm). B. Immunofluorescence staining of HSD10 alone (red), mitochondrial marker 
SODII alone (green), and these two antigens co-localized (yellow) with DAPI (blue) in HSD10 
ov PC-12 cells (scale bar: 20 μm). C. Immunofluorescence staining of CypD alone (green), 
mitochondrial marker Hsp60 alone (red), and these two antigens co-localized (yellow) with 
DAPI (blue) in HSD10 ov PC-12 cells (scale bar: 20 μm). D-E. Quantification of HSD10 and 
CypD fluorescence densities (depicted in A) displayed as fold increase relative to EV (n=4). 
Data presented as mean ± SE. *P<0.01 versus control group. Adapted from Carlson, E.A. et al. 
(2015) BMC Cancer (152). 
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After confirming co-localization of the proteins, a Co-IP assay was performed to 
investigate HSD10-CypD interactions in the PC-12 overexpression cell lines. As shown in 
Figure 1-14, there was an enhanced interaction between HSD10 and CypD in HSD10 ov cells 
compared to EV cells, which was confirmed using both proteins as pull-down antibodies. This 
indicates that increased levels of HSD10 promote the formation of HSD10-CypD complexes. 
Taken together, the results imply that an increased abundance of HSD10 in the vicinity of 
CypD leads to HSD10-CypD complex formation in PC-12 cells, conceivably preventing cell 
death induction. These findings further solidify the concept that HSD10 is important in 
promoting cancer growth and maintenance. 
 
 
Figure 1-14: Enhanced interaction between HSD10 and CypD in PC-12 HSD10-
overexpression cells. EV and HSD10 ov whole cell lysates were subjected to Co-IP with pull-
down antibodies (3 μl rabbit anti-HSD10, 2 μl mouse anti-CypD, 3 μl rabbit IgG or 3 μl mouse 
serum). Immunoblotting was used to reveal the immunoprecipitated proteins with mouse anti-
CypD (1:8000), rabbit anti-HSD10 (1:3000), and mouse anti-Actin (1:8000) as the loading 
control for the input. Adapted from Carlson, E.A. et al. (2015) BMC Cancer (152). 
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1.8. Impact of CypD-knockdown on Altered Pheochromocytoma Cells 
 After observing co-localization and enhanced binding between HSD10 and CypD in the 
PC-12 overexpression cells, the possible link was further studied via transient transfection with a 
siRNA oligonucleotide (Table 7) to knockdown CypD in the PC-12 HSD10 ov cells. 
Immunoblot analysis showed a 45% reduction in CypD protein expression in the HSD10 
ov-CypD siRNA cells compared to the HSD10 ov-control siRNA cells (Fig. 1-15 A). Also, the 
HSD10 ov-CypD siRNA cells exhibited a decrease in HSD10 protein (Fig. 1-15 B). This data, 
taken together with Figure 1-12 C and D, shows that upon HSD10-knockdown, CypD protein is 
reduced and that after CypD-knockdown, HSD10 protein is decreased. This provides further 
evidence that HSD10 and CypD are connected in cancer cells. 
 
 
Figure 1-15: CypD-knockdown in PC-12 HSD10 ov cells. After transient transfection, PC-12 
HSD10 ov cells were harvested for detection of protein expression using mouse anti-CypD 
antibody (1:6000) and rabbit anti-HSD10 antibody (1:2000) via immunoblotting. Actin (mouse 
anti-Actin antibody, 1:8000) was used as the loading control, and CypD and HSD10 expression 
were normalized to actin. A-B. Whole cell lysates were analyzed for CypD (A) and HSD10 (B) 
protein expression (n=4). Results are displayed as fold increase relative to control siRNA. Data 
presented as mean ± SE. *P<0.05 versus control siRNA group. 
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The effect of CypD knockdown on PC-12 HSD10 ov cell growth was examined using in 
vitro cell culture. Following transient transfection with CypD siRNA (Table 7), PC-12 HSD10 
ov cells were plated in dishes at a constant density and grown over the course of seven days, with 
a dish counted each day. As demonstrated in Figure 1-16, both transfected cell groups grew at a 
similar rate during the first three days. By the fourth day, the CypD siRNA group had slightly 
fewer total cells compared to the control siRNA group.  
The remainder of the days exhibited a trend toward reduced growth rate in the CypD 
siRNA cells in comparison to the control siRNA cells (Fig. 1-16). However, this decrease did not 
reach statistical significance, likely due to the extreme proliferative capabilities of the PC-12 
HSD10 ov cells promoted by HSD10 itself. Thus, it would be beneficial to investigate the effect 
of CypD knockdown in PC-12 EV cells. Nevertheless, the trend toward decreased cell growth 
rate in the CypD siRNA cells suggests that HSD10 and CypD are associated in cancer. 
 
 
Figure 1-16: Effect of CypD-knockdown on in vitro PC-12 HSD10 ov cell growth. PC-12 
HSD10 ov cells were plated at a constant density and transiently transfected using siRNA. Next, 
cells were counted over 7 days to determine cell growth rate. Growth curve of control siRNA 
(black ■) and CypD siRNA (black striped ■) cells displayed as cells x 10
4
 per ml (n=4). Data 
presented as mean ± SE.  
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Next, the enzyme activity of ETC complex IV was tested to investigate whether CypD 
knockdown impacts mitochondrial respiration in PC-12 HSD10 ov cells. Complex IV enzyme 
activity was unchanged between the control siRNA and CypD siRNA groups (Fig. 1-17 A), 
suggesting that knockdown of CypD does not influence ETC functionality in the highly 
productive PC-12 HSD10 ov cells.  
To confirm that CypD knockdown does not change the ETC system in PC-12 HSD10 ov 
cells, ATP content was assessed. In addition to the complex IV data, the level of ATP was 
unaltered in CypD siRNA cells compared to control siRNA cells (Fig. 1-17 B).  
Together, the data implies that CypD knockdown does not affect PC-12 HSD10 ov cell 
respiration. This is not overly surprising, as CypD mainly functions as cell death inducer and 
may not be involved in energy metabolism. Thus, loss of CypD would not directly impact 
mitochondrial bioenergetics, especially in cells with an overabundance of HSD10, an enzyme 
which can influence many mitochondrial processes including metabolism. 
 
 
Figure 1-17: Consequence of CypD-knockdown on ETC complex IV enzyme activity and 
ATP level in PC-12 HSD10 ov cells. Following transient transfection, PC-12 HSD10 ov cells 
were harvested and tested for ETC complex IV enzyme activity (A) and cellular ATP content 
(B). Results are displayed as fold increase relative to control siRNA (n=4 for each assay). Data 
presented as mean ± SE.  
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As CypD is mainly involved in cell death induction, TUNEL staining was performed in 
the siRNA-transfected PC-12 HSD10 ov cells after treatment with 0 mM or 0.75 mM H2O2 for 
24 hours (Fig. 1-18 A). As anticipated, both control siRNA and CypD siRNA cells treated with 
H2O2 displayed higher percentages of cells undergoing apoptosis (Fig. 1-18 B, *p-values), 
compared to the untreated matched control groups. A small trend toward greater cell death 
induction was observed in the CypD siRNA untreated group in comparison with the control 
siRNA group, although there was no statistical significance, providing a possible explanation for 
the small trend of decreased growth rate observed in the CypD siRNA group. Intriguingly, the 
CypD siRNA treatment group had significantly more TUNEL staining compared to the control 
siRNA treatment group (Fig. 1-18 B, #p-value), demonstrating that PC-12 HSD10 ov cells with 
less CypD are more susceptible to stress-induced apoptosis induction.  
CypD has been observed to be overexpressed in many cancers (83), which often provides 
cancer cells protection against cell death due to its peptidyl prolyl isomerization activity (160). 
Similar to the data presented in Figure 1-18, Machida and associates previously showed that 
CypD-deficiency sensitized rat glioma cells to apoptosis (59). This implies that reducing the high 
amounts of endogenous CypD in certain cancer cells leads to induction of cell death. 
Additionally, it is thought that interactions between CypD and specific mitochondrial 
proteins may be responsible for the anti-apoptotic phenomenon seen in cancers overexpressing 
CypD. For instance, binding of CypD to Bcl-2 (58) or HK-II (59) has been observed to suppress 
apoptotic cell death in cancer cells. Thus, Figure 1-18 provides further support of this concept 





Figure 1-18: Effect of CypD-knockdown on oxidative stress-induced cell death in PC-12 
HSD10 ov cells. After transient transfection, cell death induction was assessed in PC-12 HSD10 
ov cells. A. Confocal microscopy demonstrating TUNEL staining of cells undergoing apoptosis 
(green), nuclear staining with DAPI (blue), and these two antigens co-localized (merged) in 
control siRNA and CypD siRNA cells treated with 0 mM and 0.75 mM H2O2 for 24 hours. Scale 
bar in A: 30 μm. B. Quantification of control siRNA and CypD siRNA cell TUNEL staining 
(depicted in A) displayed as the percentage of TUNEL positive cells (n=10). Data presented as 
mean ± SE. *P<0.01, **P<0.001 versus control siRNA and CypD siRNA non-treatment groups; 






1.9. Interim Conclusion 
 Chapter 1 examined the effect of HSD10 modification in rat pheochromocytoma cells to 
assess the importance of HSD10 in cancer (Fig. 1-19). Overexpression of HSD10 in PC-12 cells 
was associated with increased energy production, enhanced cell growth rate, and protection 
against stress-induced cell death induction. This was likely due to the enhanced complex 
formations between HSD10 and CypD. 
Knockdown of HSD10 in PC-12 cells correlated with reduced energy production, 
decreased cell growth rate, and diminished resistance against stress-induced cell death, possibly 
caused by the lost interaction of HSD10 with CypD. Furthermore, knockdown of CypD in PC-12 
HSD10 ov cells was accompanied by increased susceptibility of cells to stress-induced cell death 
induction; however, no changes were observed in energy production. 
Taken altogether, these results suggest that HSD10 plays an important role in cancer cell 
growth and energy metabolism. Moreover, the data indicates that HSD10 and CypD together are 
involved in cancer cell resistance to cell death. Additional studies are needed to further examine 




Figure 1-19: Chapter 1 summary of the effect of HSD10 on PC-12 cancer cell progression. 
Black arrows: increased HSD10 in PC-12 cells correlates with increased HSD10-CypD complex 
formation, enhanced mitochondrial membrane stabilization, and heightened energy production; 
this leads to cancer cell survival through enhanced cellular resistance to cell death, resulting in 
increased cancer cell growth. Gray arrows: decreased HSD10 in PC-12 cells is associated with 
mitochondrial membrane disruption, reduced energy production, and decreased CypD protein; 
this results in reduced cancer cell survival due to stress-induced cell death. Black-striped arrows: 
decreased CypD in PC-12 HSD10 ov cells is accompanied by reduced HSD10 protein, but no 









Chapter 2: Influence of HSD10 on Altered Breast Cancer Cells 
 
Although early detection and improved treatments have increased patient survival rates 
(161), breast cancer remains the second leading cause of cancer-related deaths among women 
(162). This is largely due to rapid replication of tumor cells and enhanced resistance to available 
breast cancer therapies. After initially determining that HSD10 may promote tumor growth in 
pheochromocytoma cells, the role of HSD10 in cancer was further investigated in relation to 
human breast cancer. Using similar techniques from Chapter 1, breast cancer cell growth rate 
was observed in wild type cells to determine growth patterns and correlations in regard to 
HSD10 endogenous expression.  
The MCF7, MCF10A, MDA-MB-231, and T47D breast cancer cell lines were used for 
the HSD10 transfection studies detailed in Section 2.3. and onward in this chapter. As in 
Chapter 1, breast cancer cell growth rate was observed in HSD10-transfected cell lines to 
determine if HSD10 influences breast tumor cell proliferation in cell culture. Once it was 
observed that HSD10 alteration correlates with differing growth patterns in breast cancer cells, 
mitochondrial processes were examined to explore the impact of HSD10 on intracellular 
function. The goal of this chapter was to establish working models of human breast cancer cell 





2.1. HSD10 Content in Wild-Type Breast Cancer Cell Lines 
To investigate the role of HSD10 in breast cancer cells, the relative amount of HSD10 
was measured in a panel of wild-type human breast cancer cell lines (Fig. 2-1). Upon 
comparison of the relative expression levels of HSD10 total RNA in the panel of human breast 
cancer cell lines, the MCF10A, MCF7, and MDA-MB-231 cell lines were chosen for HSD10 
overexpression as they all exhibited low to median levels of HSD10 (Fig. 2-1, Lane 2 green 
bar, Lane 4 red bar, and Lane 9 purple bar). Additionally, MCF10A cells are described as 
non-tumorigenic breast cells compared to other breast cancer cell lines; thus these cells were 
used to investigate whether HSD10 is a tumor-initiating factor. Furthermore, T47D cells were 
selected for HSD10 knockdown since this line had considerably high levels of HSD10 relative to 







Figure 2-1: Abundance of HSD10 in a panel of breast cancer cell lines. Total RNA isolated 
from multiple human breast cancer cell lines was transcribed into cDNA and subjected to qRT-
PCR with primers for human HSD10. qRT-PCR was normalized against GAPDH and relative 
HSD10 expression levels were calculated using a standard curve. Lanes: 1) HMEC, 2) MCF10A, 
3) MCF12A, 4) MCF7, 5) BT474, 6) BT483, 7) BT549, 8) HS578T, 9) MDA-MB-231,                   
10) MDA-MB-453, 11) MDA-MB-468, 12) SKBR3, 13) SUM52, 14) SUM149, 15) SUM159, 
16) SUM185, 17) T47D. 
 
These four human breast cancer cell lines were used for further studies, in addition to rat 
pheochromocytoma cells (Table 10). Immunoblot analysis of the selected cell lines further 
demonstrated HSD10 protein expression patterns, which were similar to that of the total RNA 
content depicted in the breast cancer panel for T47D, MCF7, MCF10A, and MDA-MB-231 cells 
(Fig. 2-2 A). CypD protein levels correlated with the expression pattern of HSD10 for the four 
breast cancer cell lines (Fig. 2-2 B). 
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Before altering HSD10 content in the chosen breast cancer cell lines for the studies 
detailed in later in this chapter, these wild-type cells were evaluated for natural cell growth rate. 
 
 
Figure 2-2: HSD10 and CypD protein expression pattern in four breast cancer cell lines. 
Wild-type T47D, MCF7, MCF10A, and MDA-MB-231 breast cancer cells were harvested for 
detection of protein expression using rabbit anti-HSD10 antibody (1:1000) and mouse anti-CypD 
antibody (1:8000) via immunoblotting. Actin (mouse anti-Actin antibody, 1:4000) was used as 
the loading control with HSD10 and CypD expression both normalized to actin. A. Whole cell 
lysates were analyzed for HSD10 protein expression (n=3 for all groups). B. Whole cell lysates 








2.2. In Vitro Wild-Type Breast Cancer Cell Growth Curve Analysis 
In order to determine baseline cell growth and observe natural cell behavior for the four 
breast cancer cell lines, cell growth curves over ten days were performed using wild-type T47D, 
MCF7, MCF10A, and MDA-MB-231 cells. As depicted in Figure 2-3, MCF10A cells initially 
grew at a faster rate compared to T47D and MCF7 cells. Interestingly, MCF10A cells grow in a 
monolayer formation; once the dish is covered, the growth of new cells appeared to decline and 
the current cells sickened and died (Fig. 2-3, green line, MCF10A downward curve trend from 
days 7-10). This growth pattern is consistent with the specific cell type: MCF10A is a non-
tumorigenic breast cell line in which the cells form a monolayer and do not form large masses 
when growth space is limited.  
Clumping of cells into large masses is indicative of a tumorigenic cell line, which was 
exhibited by both T47D and MCF7 cells. These two cell types grew very slowly in clumped 
groups in the initial days of the growth curve (Fig. 2-3, days 1-3). By the fourth day, cell growth 
had increased and remained fairly constant throughout the rest of the experiment. In the end, the 
T47D cell line attained the highest number of cells out of the four cell lines (Fig. 2-3, blue line, 
day 10), and the MCF7 cells reached a little over half of the total T47D cell number (Fig. 2-3, 
red line, day 10). Both of these cell lines continued to grow in large clumps across the surface of 
the dish and did not form a monolayer, indicative of a carcinoma cell line.  
The metastatic MDA-MB-231 cell line grew at a rate similar to the T47D and MCF7 
cells (Fig. 2-3, purple line, days 1-6). Intriguingly, the cells formed a monolayer first and then 
began clumping as space became limited. Over days seven through ten, the MDA-MB-231 cell 




Figure 2-3: Natural cell growth pattern in four breast cancer cell lines. T47D, MCF7, 
MCF10A, and MDA-MB-231 cells were plated at a constant density and counted over the course 
of 10 days for determination of wild-type cell growth rate. MCF10A (green ■) cells initially 
grew at a faster rate compared to the other cell lines, but climaxed around day 7. The T47D (blue 
■) and MCF7 (red ■) cell lines grew at a constant rate, although MCF7 cells grew more slowly 
in comparison to T47D cells. MDA-MB-231 (purple ■) cells grew at a rate similar to the T47D 











2.3. Generation of HSD10-transfected Breast Cancer Cell Lines 
Succeeding lentiviral transfection, MCF7, MDA-MB-231, and MCF10A cells expressing 
either an empty CSCW vector or an HSD10 overexpression CSCW vector (Table 9) were 
subjected to immunoblotting for analysis of protein content. HSD10 protein expression was 
increased by approximately 2-fold in MCF10A HSD10 ov cells (Fig. 2-4 A), MDA-MB-231 
HSD10 ov cells (Fig. 2-4 C), and MCF7 HSD10 ov cells (Fig. 2-4 D) in comparison with the 
respective controls.  
Additionally, HSD10 knockdown was performed in T47D cells via lentiviral transfection 
using a shRNA oligonucleotide (Table 7). Immunoblot analysis determined that HSD10 protein 
expression was significantly reduced by 70% in T47D HSD10 shRNA-transfected cells in 
comparison with T47D control shRNA-transfected cells (Fig. 2-4 B). These experiments verify 
that HSD10 overexpression in MCF7, MDA-MB-231, and MCF10A cells and HSD10 






Figure 2-4: Generation of HSD10-transfected breast cancer cells. MCF10A, T47D, MDA-
MB-231, and MCF7 transfected cells were harvested for detection of protein expression using 
rabbit anti-HSD10 antibody (1:3000) via immunoblotting. Actin (mouse anti-Actin antibody, 
1:8000) was used as the loading control and HSD10 expression was normalized to actin. A. 
MCF10A EV and HSD10 ov whole cell lysates were analyzed for HSD10 protein expression and 
displayed as fold increase relative to MCF10A EV (n=3). B. T47D Control shRNA and HSD10 
shRNA whole cell lysates were analyzed for HSD10 protein expression and displayed as fold 
increase relative to T47D control shRNA (n=3). C. MDA-MB-231 EV and HSD10 ov whole cell 
lysates were analyzed for HSD10 protein expression and displayed as fold increase relative to 
MDA-MB-231 EV (n=4). D. MCF7 EV and HSD10 ov whole cell lysates were analyzed for 
HSD10 protein expression and displayed as fold increase relative to MCF7 EV (n=4). Data 
presented as mean ± SE. *P<0.05, **P<0.01 versus control group. 
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2.4. Localization of HSD10 in HSD10-transfected Breast Cancer Cells 
Furthermore, to ensure that the effects observed in HSD10-transfected breast cancer cells 
were not due to impaired localization of excess HSD10, immunofluorescence staining of all 
modified breast cancer cell lines was used to show the localization of HSD10 to mitochondria. 
Similar to the previous observations in the PC-12 cells (Chapter 1), the fluorescence 
intensity of HSD10 was significantly increased in MCF10A HSD10 ov cells in comparison with 
MCF10A EV cells (Fig. 2-5 A-B). Additionally, the merged picture of Figure 2-5 A 
demonstrates increased localization of HSD10 to mitochondria in the MCF10A HSD10 ov cells. 
Similar HSD10 staining intensity and mitochondria localization was observed in the MDA-MB-
231 HSD10 ov cells (Fig. 2-5 E-F) and MCF7 HSD10 ov cells (Fig. 2-5 G-H), compared with 
the respective EV control cells. Furthermore, the intensity of HSD10 staining was decreased in 
T47D HSD10 shRNA cells compared to T47D control shRNA cells (Fig. 2-5 C-D), confirming 
the success of HSD10 knockdown.  
As in the PC-12 cells (Chapter 1), upregulation of HSD10 does not appear to affect the 
mitochondrial localization of the enzyme. Also, downregulation of HSD10 does not seem to 
hinder mitochondrial targeting. The diminished co-staining of HSD10 with Mito Tracker Red is 




Figure 2-5: Localization of HSD10 in HSD10-transfected breast cancer cells. MCF10A, 
T47D, MDA-MB-231, and MCF7 transfected cells were cultivated on chamber slides and 
proteins were detected using mouse anti-HSD10 antibody (1:300) and Mito Tracker Red (1:500). 
After incubation with anti-mouse Alexa Fluor 488 (1:500), cells were mounted in fluorescence 
mounting media. Confocal microscopy was used to visualize immunofluorescence staining of A. 
GFP alone (green), Mito Tracker Red alone (red), HSD10 alone (blue), and these three antigens 
co-localized (white) in EV and HSD10 ov MCF10A cells (scale bar: 20 μm). B. Quantification 
of HSD10 immunofluorescence staining (depicted in A) displayed as fold increase relative to 
MCF10A EV (n=6). C. Immunofluorescence staining of HSD10 alone (green), Mito Tracker 
Red alone (red), and merged with blue DAPI nuclear staining (yellow) in control shRNA and 
HSD10 shRNA T47D cells (scale bar: 20 μm). D. Quantification of HSD10 immunofluorescence 
staining (depicted in C) displayed as fold increase relative to T47D control shRNA (n=6). E. 
GFP alone (green), Mito Tracker Red alone (red), HSD10 alone (gray), and these three antigens 
co-localized (white) in EV and HSD10 ov MDA-MB-231 cells (scale bar: 20 μm). F. 
Quantification of HSD10 immunofluorescence staining (depicted in E) displayed as fold increase 
relative to MDA-MB-231 EV (n=10). G. GFP alone (green), Mito Tracker Red alone (red), 
HSD10 alone (gray), and these three antigens co-localized (white) in EV and HSD10 ov MCF7 
cells (scale bar: 20 μm). H. Quantification of HSD10 immunofluorescence staining (depicted in 
G) displayed as fold increase relative to MCF7 EV (n=10). Data presented as mean ± SE. 















2.5. In Vitro HSD10-transfected Breast Cancer Cell Growth Curve Analysis 
The consequence of HSD10 alteration on breast cancer cell growth was studied using in 
vitro cell culture growth curves. MCF10A HSD10-overexpression, T47D HSD10-knockdown, 
MDA-MB-231 HSD10-overexpression, and MCF7 HSD10-overexpression cell lines were plated 
at a constant density in 100-mm dishes and grown over the course of nine to ten days, with a dish 
counted every day. Interestingly, MCF10A HSD10 ov cells grew at approximately the same rate 
as MCF10A EV cells over nine days until the dishes were fully confluent (Fig. 2-6 A).  
This data suggests that HSD10 may not be a tumor-initiating factor, since overexpression 
did not affect growth rate in the non-tumorigenic MCF10A cells. Instead, it is highly probably 
that HSD10 is a tumor-promoting factor in previously-induced cancer cells, based on much of 
the evidence in this dissertation. Due to the growth curve results in Fig. 2-6 A and the theory that 
HSD10 is not a tumor-initiator, the MCF10A cell line was viewed as a poor candidate for the 
creation of an HSD10-overexpression stably transfected cell model. 
Knockdown of HSD10 in T47D cells led to a considerable decrease in growth rate 
compared with control shRNA T47D cells (Fig. 2-6 B). This result matched the PC-12 HSD10-
knockdown growth curve depicted in Chapter 1. As T47D cells are true cancer cells, this result 
implies that HSD10 may promote cancerous cell growth in cell culture, while having little to no 
effect in non-cancerous breast cells. Considering the growth curve results, the T47D cell line was 
subjected to further testing for corroboration that it would be a successful HSD10-knockdown 
stably transfected cell model.  
Overexpression of HSD10 in MDA-MB-231 cells did not result in any change in cell 
growth rate (Fig. 2-6 C), despite the fact that it is a metastatic cancer cell line. It is possible that 
this observation is due in part to the lack of endocrine receptors in the MDA-MB-231 cell line 
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(163). As HSD10 plays a role in steroidogenesis, and many HSD17B family members have been 
implicated in hormone-related cancers, it is plausible that ER-negative breast cancers are not 
influenced by HSD10. Further study is needed to investigate this possibility. 
Last, HSD10 overexpression in MCF7 cells did not elicit any statistically significant 
changes in cell growth rate. There was a slight increase in MCF7 HSD10 ov cell growth from 
days seven to nine (Fig. 2-6 D), compared to MCF7 EV cells. This may be explained by the 
ability of HSD10 to limit stress-induced cell death. Once the dishes were confluent on the sixth 
day, the MCF7 EV cells may have been unable to compete for space and thus underwent 
apoptosis. In contrast, it is possible that the MCF7 HSD10 ov cells were able to continue 
growing and remained protected from cell death induction due to the high amounts of HSD10.  
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Figure 2-6: Effect of HSD10-modification on in vitro breast cancer cell growth. MCF10A, 
T47D, MDA-MB-231, and MCF7 transfected cells plated at a constant density were grown and 
counted over the course of 9-10 days to determine cell growth rate. A. Growth curve of MCF10A 
EV (dark green ■) and MCF10A HSD10 ov (light green ■) cells displayed as cells x 10
4
 per ml 
(n=4). B. Growth curve of T47D control shRNA (dark blue ■) and T47D HSD10 shRNA (light 
blue ■) cells depicted as cells x 10
4
 per ml (n=4). C. Growth curve of MDA-MB-231 EV (dark 
purple ■) and MDA-MB-231 HSD10 ov (light purple ■) cells displayed as cells x 10
4
 per ml 
(n=4). D. Growth curve of MCF7 EV (dark red ■) and MCF7 HSD10 ov (light red ■) cells 
displayed as cells x 10
4
 per ml (n=4). Data presented as mean ± SE. *P<0.01, **P<0.001, 






2.6. Effect on Altered Breast Cancer Mitochondrial Function 
As mitochondrial functions were altered upon HSD10-transfection in the PC-12 cells 
(Chapter 1), the effect of HSD10 on mitochondrial function was also studied in the modified 
breast cancer cells. ETC complex I, II, III, and IV enzyme activities were tested to examine the 
effect of HSD10 alteration on mitochondrial respiration.  
Interestingly, complex I enzyme activity for the T47D-transfected cells remained 
unchanged between the two groups (Fig. 2-7 A), while complexes II and III had a slight trend 
toward decreased activity in HSD10 shRNA cells in comparison with control shRNA cells (Fig. 
2-7 B-C), although not statistically significant. Complex IV enzyme activity was greatly 
diminished in the HSD10 shRNA group compared to the control shRNA group (Fig. 2-7 D).  
The differences observed in the T47D-transfected cells as compared to the PC-12-
tranfected cells used previously may be explained by focusing on the natural levels of HSD10 in 
the wild-type cells. Since wild-type T47D cells express very high levels of endogenous HSD10, 
perhaps these cells are able to compensate for HSD10 knockdown to a greater degree than wild-
type PC-12 cells which express mid-range levels of HSD10. 
Regardless of the disparities, the statistically significant reduction in complex IV enzyme 
activity and trends toward reduced complex II and III enzyme activity in the T47D HSD10 
shRNA cells parallels the decreased ETC complex enzyme activities in the PC-12 HSD10 
shRNA cells. Together, this data demonstrates that the phenotype resulting from HSD10 





Figure 2-7: Examination of ETC enzyme activities in HSD10-transfected breast cancer 
cells. T47D transfected cells were harvested and tested for ETC complex I (A), II (B), III (C), 
and IV (D) enzyme activities. Results are displayed as fold increase relative to control shRNA 
(n=5 for each assay). Data presented as mean ± SE. *P<0.001 versus control group.  
 
Lastly, since complex IV enzyme activity was reduced in T47D HSD10 shRNA cells, 
ATP production was assessed to determine the effect of this change. Similar to the PC-12 
HSD10 shRNA cells in Chapter 1, the level of ATP was significantly reduced in T47D HSD10 
shRNA cells compared to T47D control shRNA cells (Fig. 2-8). This provides further evidence 
that HSD10 alteration is important across two cancer cell lines. 
99 
 
Figure 2-8: Assessment of ATP production in HSD10-transfected breast cancer cells. T47D 
transfected cells were harvested for determination of cellular ATP content. Densitometry of 
results displayed as fold increase relative to control shRNA (n=4). Data presented as mean ± SE. 












2.7. Interim Conclusion 
 Chapter 2 investigated the effect of HSD10 alteration in a different type of human 
cancer to confirm or disprove the importance of HSD10 across cancers. Since overexpression of 
HSD10 did not induce MCF10A cancer development, it is probable that HSD10 is a tumor-
promoting factor (Fig. 2-9). Therefore, it is likely that HSD10 alteration is more problematic in 
cancerous cells, as compared to non-tumorigenic cells. 
 Additionally, knockdown of HSD10 in T47D cells displayed a similar phenotype to the 
PC-12 HSD10-knockdown cells. This shows that the resultant phenomenon following HSD10 
alteration is conserved across two known cancer cell lines, providing further evidence that 
HSD10 has an integral role in cancer growth. Further studies are necessary to examine whether 
the HSD10-mediated phenotype is observed in other cancer types, and to determine which 
cancers are most affected. 
 
 
Figure 2-9: Chapter 2 summary of the effect of HSD10 on cancer cell progression.  
In cancer cells, increased HSD10 levels correlate with increased HSD10-CypD complex 
formation, enhanced mitochondrial membrane stabilization, and heightened energy production. 
This leads to cancer cell survival through enhanced cellular resistance to cell death, resulting in 







Chapter 3: The Future Outlook for HSD10 in Cancer 
 
Upon determination of the significant role HSD10 plays in PC-12 cancer progression in 
Chapter 1 and testing four human breast cancer cell lines with HSD10 alteration in Chapter 2, 
several future directions for this project will be outlined in the following chapter. 
To begin, it is highly recommended that stably-transfected cell lines with HSD10 
overexpression and HSD10 knockdown be created prior to performing any experiments. 
Essentially, stable expression of HSD10 will yield more accurate results over a longer period of 















3.1. Stable Expression of HSD10 in Breast Cancer Cell Lines 
The goal of Chapter 2 was to establish working models of human breast cancer cell lines 
with differential expression of HSD10. Out of the four studied cell lines, it was anticipated that 
two would be chosen for creation of stable cell lines. 
Lentiviral transfection significantly increased HSD10 protein content in the MCF10A and 
MDA-MB-231 cell lines (Fig. 2-4 A and C). However, this was not accompanied by changes in 
cell growth rate (Fig. 2-6 A and C). Thus, it was determined that the MCF10A and MDA-MB-
231 cell lines were unsuitable candidates for stable transfection. 
On the contrary, lentiviral transfection significantly decreased HSD10 protein expression 
in the T47D cell line (Fig. 2-4 B), which correlated with a marked reduction in cell growth rate 
(Fig. 2-6 B). Following the successful change in T47D cell growth after HSD10 knockdown, 
ETC complex enzyme activities and ATP content were examined. Reductions in complex IV 
enzyme activity and ATP levels were detected, demonstrating that the HSD10 knockdown cell 
phenotype was consistent to the observations in PC-12 cells (Chapter 1). Therefore, the T47D 
breast cancer cell line is considered an appropriate candidate for stable knockdown of HSD10. 
Interestingly, lentiviral transfection significantly increased HSD10 protein content in the 
MCF7 cell line (Fig. 2-4 D), which was accompanied by a trend toward enhanced cell growth 
rate (Fig. 2-6 D), although there was no statistical significance. Due to time constraints, ETC 
complex enzyme activity and ATP levels were not tested. However, despite the limited change in 
cell growth, it is recommended to use the MCF7 breast cancer cell line for preliminary studies of 
stable overexpression of HSD10. It is possible that stable transfection will provide more accurate 
evidence as to whether or not HSD10 overexpression affects MCF7 cell growth rate. 
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3.2. In Vitro and In Vivo Analysis of Stably-transfected HSD10 Breast Cancer Cell Lines 
 Upon the creation of stable breast cancer cell lines, immunoblotting and 
immunofluorescence staining should be done to verify the degree of successful overexpression or 
knockdown of HSD10 in the cell lines.  
Next, in vitro cell growth rate curves must be performed to examine whether the stable, 
artificial overexpression or knockdown of endogenous HSD10 influences breast cancer cell 
growth rate. Due to the success of lentiviral HSD10 knockdown correlating with diminished 
T47D cell growth rate (Fig. 2-6 B), it is expected that the stable reduction of HSD10 in the same 
cell line will yield comparable results. In regards to the MCF7 cell line, which showed a trend 
toward increased cell growth following lentiviral HSD10 overexpression (Fig. 2-6 D), it is 
possible that the stable overexpression of HSD10 in MCF7 cells will reveal that cell growth rate 
is affected by HSD10 alteration in the cells. If this observation is made, then the MCF7 cell line 
is an appropriate model to study the effect of stable HSD10 overexpression in breast cancer. If 
no changes in the MCF7 cells are observed, then other breast cancer cell lines will need to be 
assessed to achieve a suitable cell line for stable overexpression of HSD10. The panel of breast 
cancer cell lines depicted in Figure 2-1 should be utilized to choose cell lines with low to 
median levels of endogenous HSD10, which will simplify experiments for artificial 
overexpression of HSD10. Additionally, since wild-type MCF7 cells exhibit median levels of 
endogenous HSD10, this cell line may also be used as an alternative HSD10 knockdown model 
in addition to the T47D cell line. 
Once two stably-transfected breast cancer cell lines, which yield significant effects on 
cell growth, have been generated, the subsequent step is to analyze the phenotype of the stable 
cell lines in animals. As cancer cells often behave differently in cell culture dishes as compared 
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to a living organism, it is necessary to investigate whether the stably-modified breast cancer cell 
lines will exhibit similar growth patterns under more natural parameters, such as the tumor-
microenvironment and nutrient-rich conditions. Based on Figure 1-4, female SCID mice provide 
a suitable model for observing tumor formation in vivo. Thus, it is recommended that mammary 
fat-pad injections of the stably-transfected cell lines be performed in mice. Tumors should be 
monitored and measured several times per week, for at least three months, or until humane 
endpoints are reached. The length of time necessary for tumor nodules to form will vary 
depending on the cell line and inoculation volume; however, T47D and MCF7 cells typically 
need at least three months to form (164, 165). If HSD10 levels affect in vivo tumor growth using 
the stably-modified breast cancer cells, similar to the observations in the stably-transfected PC-
12 in vivo tumor study (Fig. 1-4), it provides more convincing, clinically significant evidence 
that HSD10 plays a key role in breast cancer progression.  
After it is confirmed that stable overexpression and knockdown of HSD10 influence 
breast cancer in vitro cell growth and in vivo tumor formation, the effects of HSD10-
modification on cellular function must be analyzed. Although the experiments detailed in 
Chapter 1 provide an in-depth assessment and convincing data for the impact of HSD10-
alteration on cancer cell function, this work was all performed in a rat adrenal gland tumor cell 
line. While the rat is a well-established animal model for investigating human disease states, rat 
cells alone will not provide adequate information for translation into human disease for clinical 
study. Therefore, it is highly advised to examine cellular function in the stably-transfected 
human breast cancer cell lines utilizing the same techniques performed in the PC-12 cells. 
Since HSD10 is a mitochondrial enzyme, mitochondrial function must be examined by 
assessing ETC complex I, II, III, and IV enzyme activities, as well as ATP content in the 
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HSD10-modified breast cancer cells. Additionally, testing mitochondrial membrane permeability 
in the stably-transfected breast cancer cells will provide information regarding the health of the 
mitochondria. This will lead to the investigation of cellular resistance to oxidative stress 
conditions using functional assays such as complex enzyme activity. If HSD10-alteration confers 
the breast cancer cells resistance capabilities, cell death assays such as TUNEL staining must be 
used for clarification. As similar results for complex IV enzyme activity and cellular ATP 
content were obtained in the lentiviral HSD10 knockdown T47D cells (Fig. 2-7 D and Fig. 2-8) 
compared to the PC-12 HSD10 knockdown cells (Fig. 1-5 D and Fig. 1-7), it is anticipated that 
the growth and cellular function-related phenotypes associated with HSD10 reduction will 
remain accurate for the stable HSD10 knockdown T47D cell line. 
Once the phenotypes previously observed for HSD10 overexpression and knockdown are 
further solidified with evidence in the stable breast cancer cell lines, the mechanism of action for 
HSD10 in cancer progression needs to be thoroughly investigated. Chapter 1 began to examine 
the physical interaction of HSD10 with CypD in the PC-12 cells. The studies need to be 
performed in the stably-transfected human breast cancer cell lines, including immunoblotting and 
co-immunofluorescence staining to assess the impact of HSD10 overexpression or reduction on 
CypD protein levels, as well as Co-IPs under baseline and oxidative stress conditions to examine 
whether HSD10 and CypD interact in the modified breast cancer cells. If the phenotype data of 
HSD10-modification is sustained in PC-12 cells, it is likely that the interaction between HSD10 
and CypD will occur in different cell lines as well. Furthermore, CypD translocation studies 
using mitochondrial matrix and IM fractions need to be performed to examine the impact of 
HSD10 on CypD function. According to our overall hypothesis, overexpression of HSD10 in 
cancer cells limits the ability of CypD to translocate to the IM under stress conditions, thereby 
106 
preventing cell death induction; this results in the enhanced cell growth rate in the HSD10 
overexpression cells. Thus, these studies would determine if the interaction of HSD10 with 
CypD is preventing the translocation of CypD to the IM in the stable HSD10 overexpression 
breast cancer cells. Likewise, CypD translocation should be examined in the stable HSD10 
knockdown breast cancer cells to assess whether reduction in HSD10 disrupts its interaction with 
CypD, thus permitting CypD to translocate to the IM and induce cell death. 
In addition to examining the physical interaction between HSD10 and CypD, knockdown 
and overexpression studies targeting CypD can be performed to investigate the interface between 
the two proteins. Chapter 1 also began to study the role of HSD10 with CypD by using siRNA 
to reduce CypD protein in the PC-12 HSD10 ov cells. As siRNA transfection efficacy and 
duration is often transitory (166), it is advised to use a CypD-specific shRNA oligonucleotide 
(167) for transfection in the breast cancer cells. Wild-type T47D cells are an appropriate choice 
for CypD knockdown, as the cells express high levels of endogenous HSD10 and CypD. 
Following CypD knockdown, immunoblotting and immunofluorescence must be done to confirm 
the degree of CypD protein reduction in the human breast cancer cells. Next, studies should be 
completed to assess whether the phenotype of CypD-modification matches the phenotype 
observed for HSD10-alteration. An in vitro cell growth curve should be performed to examine 
how knockdown of CypD affects breast cancer cell growth rate; if there is difference in cell 
growth, an in vivo study would provide further evidence as to whether CypD knockdown has any 
impact on tumor formation in animals. Furthermore, Co-IPs, CypD translocation, and cell death 
assays would determine whether reduction of CypD effects the HSD10-CypD interaction and 
cell death induction to a similar degree as HSD10 knockdown. If the phenotypes of CypD 
knockdown and HSD10 reduction are equivalent in the same cell line, such as the T47D breast 
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cancer cells, the evidence will successfully demonstrate that HSD10 mediates breast cancer cell 
growth rate and resistance to cell death induction via interaction with CypD.  
Finally, whole transcriptome RNA sequencing may be used to analyze the changing 
cellular transcriptome, post-transcriptional modifications, and gene function and expression in 
the HSD10-modified cancer cell lines. Such experiments would facilitate the identification of 



















3.3. Effect of HSD10 Inhibition on Cancer Cell Growth 
After observing the protective role of HSD10 overexpression in PC-12 cancer cells and 
the destructive consequences of HSD10 knockdown in Chapter 1, the final step of the project 
will be to examine the effect of synthesized small molecule HSD10 inhibitors (generated by the 
Yan lab (168)) on cancer cell growth.  
The synthesized A1 and A5 HSD10 inhibitor compounds (169) are structurally very 
similar, differing only by the addition of an ester group to A1 (Fig. E-A and E-B). The 
compounds exhibit comparable capacities to bind HSD10 (Fig. E-C and E-D), with A5 
displaying a slightly higher binding affinity for HSD10. Additionally, the A1 and A5 inhibitors 
disrupt HSD10 enzymatic activity to an equivalent degree (Fig. E-E and E-F), although 




Figure E: Characterization of small molecule HSD10 inhibitors. Structures of the synthesized 
small molecule HSD10 inhibitors A1 (A) and A5 (B). HSD10 inhibitors A1 (C) and A5 (D) 
bound to immobilized human recombinant HSD10 protein in a dose-dependent manner as 
depicted by Surface Plasmon Resonance (SPR); globally fit data (black lines) were overlaid with 
experimental data (red lines). SPR results of the compound binding affinities for HSD10 
revealed Kd values of 496 nM for A1 and 291 nM for A5. Inhibition of HSD10 enzymatic 
activity in the presence of the synthesized A1 (E) and A5 (F) inhibitors corresponded with Ki 
values of 96.6±19.4 μM and 14.9±1.4 μM, respectively. Adapted from Valasani, K.R. et al. 
(2014) Curr Alzheimer Res (169). 
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As shown in Figure 3-1, the HSD10 enzymatic A5 inhibitor does not disrupt HSD10 
protein expression in either PC-12 EV or HSD10 ov cells. 
 
 
Figure 3-1: HSD10 enzyme inhibition does not affect HSD10 protein expression in PC-12 
HSD10-transfected cells. PC-12 EV and HSD10 ov cells were treated with 0 μM or 150 μM A5 
inhibitor for 24 hours and then harvested for detection of HSD10 protein expression using rabbit 
anti-HSD10 antibody (1:3000). Actin (mouse anti-Actin antibody, 1:8000) was used as the 
loading control and HSD10 protein expression was normalized to actin (n=4 for each group). 
Data presented as mean ± SE. *P<0.01 versus control groups. 
 
Following treatment of PC-12 cells with the two HSD10 inhibitors, growth rate analysis 
was used to determine which HSD10 inhibitor was more effective in several of the cancer cell 
lines used in this dissertation. Additionally, the effect of HSD10 inhibition on tumor growth was 




3.3.1. In Vitro and In Vivo HSD10-transfected Pheochromocytoma Cell Growth Analysis 
with HSD10 Inhibitors 
The effect of HSD10 inhibition on PC-12 cell growth was examined using in vitro cell 
growth rate experiments. PC-12 EV and HSD10 ov cells were plated in dishes at a constant 
density, treated with 0, 50, 100, 150, 200, 250, or 300 μM A1 (Fig. 3-2) or A5 inhibitor (Fig. 3-
3), and then grown over the course of seven days. Each day, the number of cells was counted in 
one dish. Both of the HSD10 inhibitors reduced EV cell growth rate in a dose-dependent manner 
(Fig. 3-2 A and Fig. 3-3 A), with the A5 inhibitor having a more significant effect.  
There was little to no affect for either inhibitor on HSD10 ov cell growth rate (Fig. 3-2 B 
and Fig. 3-3 B). This is possibly due to the differing amounts of HSD10 between the two PC-12 
cell lines. As the HSD10 ov cells have a significantly higher abundance of artificial HSD10 and 
grow extremely fast, the same dosage of small molecule HSD10 inhibitor has a larger quantity of 
HSD10 to bind and inhibit, thus diminishing the efficacy of the compounds. Undeniably, the in 
vivo data shown in Figure 3-4 further confirms the theory that the PC-12 HSD10 ov cells are 
unaffected by the HSD10 inhibitors. The animal study revealed that there was no statistical 
difference between the untreated HSD10 ov tumors and the HSD10 ov tumors treated with the 
stronger HSD10 inhibitor A5 over one month.  
Due to these results, it is advised to study HSD10 inhibition in unmodified cancer cell 
lines with varying endogenous HSD10 levels. Additionally, cancer cells that form tumors slowly 
over the course of several months in animals would provide a better model for cancer research, 
as many cancers are considered chronic diseases that can last months or years. Ideally, slower 
growing tumors would allow more time for the HSD10 inhibitors to work toward slowing and/or 




Figure 3-2: HSD10 A1 inhibitor reduces in vitro growth rate in PC-12 EV cells. PC-12 
transfected cells were plated at a constant density in low glucose DMEM media and treated with 
0, 50, 100, 150, 200, 250, or 300 μM A1 HSD10 inhibitor. The cells were then grown and 
counted over the course of 7 days to determine cell growth rate. A. Growth curve of EV 0 μM 
A1 (red ■), EV 50 μM A1 (green ▲), EV 100 μM A1 (purple ×), EV 150 μM A1 (teal ♦), EV 
200 μM A1 (orange ●), EV 250 μM A1 (blue │), and EV 300 μM A1 (pink ▬) depicted as cells 
x 10
4
 per ml (n=4). B. Growth curve of HSD10 ov 0 μM A1 (red ■), HSD10 ov 50 μM A1 
(green ▲), HSD10 ov 100 μM A1 (purple ×), HSD10 ov 150 μM A1 (teal ♦), HSD10 ov 200 
μM A1 (orange ●), HSD10 ov 250 μM A1 (blue │), and HSD10 ov 300 μM A1 (pink ▬) 
depicted as cells x 10
4
 per ml (n=4). Data presented as mean ± SE. Pink *P<0.05, **P<0.001 for 
300 μM against 0 μM; Blue *P<0.05, **P<0.001 for 250 μM against 0 μM; Orange *P<0.05, 







Figure 3-3: HSD10 A5 inhibitor reduces in vitro growth rate in PC-12 EV cells. PC-12 
transfected cells were plated at a constant density in low glucose DMEM media and treated with 
0, 50, 100, 150, 200, 250, or 300 μM A5 HSD10 inhibitor. The cells were then grown and 
counted over the course of 7 days to determine cell growth rate. A. Growth curve of EV 0 μM 
A5 (red ■), EV 50 μM A5 (green ▲), EV 100 μM A5 (purple ×), EV 150 μM A5 (teal ♦), EV 
200 μM A5 (orange ●), EV 250 μM A5 (blue │), and EV 300 μM A5 (pink ▬) depicted as cells 
x 10
4
 per ml (n=4). B. Growth curve of HSD10 ov 0 μM A5 (red ■), HSD10 ov 50 μM A5 
(green ▲), HSD10 ov 100 μM A5 (purple ×), HSD10 ov 150 μM A5 (teal ♦), HSD10 ov 200 
μM A5 (orange ●), HSD10 ov 250 μM A5 (blue │), and HSD10 ov 300 μM A5 (pink ▬) 
depicted as cells x 10
4
 per ml (n=4). Data presented as mean ± SE. Pink *P<0.05, **P<0.0001 
for 300 μM against 0 μM; Blue *P<0.01, **P<0.001, ***P<0.0001 for 250 μM against 0 μM; 
Orange *P<0.05, **P<0.001 for 200 μM against 0 μM; Teal *P<0.05, **P<0.01 for 150 μM 




Figure 3-4: HSD10 A5 inhibitor has minimal effect on in vivo PC-12 HSD10 ov tumor 
growth. PC-12 transfected HSD10 ov cells were pretreated with either nothing or 150 μM A5 
HSD10 inhibitor 24 hours prior to injection into the mammary fat pad tissue of 8 two-month old 
female SCID mice. On Day 15, mice received either vehicle (sterilized saline) or 10 mg/kg A5 
HSD10 inhibitor via intraperitoneal injection; this was repeated every three days until the 
experiment end. Quantification of tumor growth in all SCID mice treated with vehicle (n=8; ■, 
solid line) or A5 HSD10 inhibitor (n=8; ▲, dashed line) grown over a total of 30 days, depicted 
in tumor volume (mm
3
). Data presented as mean. 
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3.3.2. In Vitro and In Vivo Breast Cancer Cell Growth Analysis with HSD10 Inhibitors 
After completing the pilot studies for the two HSD10 inhibitors in the PC-12 cells, the 
next step was to examine the effect of the compounds on wild-type cancer cell lines with 
endogenous HSD10. Due to time-constraints, 0 μM and 150 μM doses were used to test the 
efficacy of the HSD10 inhibitors in the T47D and MCF7 human breast cancer cell lines. Cells 
were plated in dishes at a constant density, treated with either 0 μM, 150 μM A1, or 150 μM A5, 
and then grown and counted over ten days.  
From the second day of the experiment, both of the HSD10 inhibitors decreased T47D 
cell growth rate (Fig. 3-5), with the A5 inhibitor having a more significant effect (Fig. 3-5, ▲ 
dotted line). Due to this promising preliminary data, it is anticipated that a T47D in vivo tumor 
model would provide an advantageous foundation for future HSD10 inhibitor studies. 
Furthermore, many studies have shown that T47D tumors often grow in animals gradually over 
three months up to one year (164). As it is theorized in Section 3.3.1 that slow growing tumors 
will allocate more time for the HSD10 inhibitors to effect tumor growth rate, the T47D cell line 
is a suitable candidate for in vivo experiments utilizing the HSD10 compounds.  
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Figure 3-5: Effect of HSD10 inhibition on in vitro T47D cell growth. T47D wild-type cells 
were plated at a constant density and treated with either 150 μM A1 or 150 μM A5 HSD10 
inhibitors. The cells were then grown and counted over the course of 10 days to determine cell 
growth rate. Growth curve of untreated control (■, solid line) versus either A1-treated (♦, dashed 
line) or A5-treated (▲, dotted line) depicted as cells x 10
4
 per ml (n=4). Data presented as mean 
± SE. #P<0.01, ##P<0.001, ###P<0.0001 versus control group for A1 inhibitor; *P<0.01, 
**P<0.0001 versus control group for A5 inhibitor. 
 
The A5 inhibitor also reduced MCF7 cell growth rate (Fig. 3-6, ▲ dotted line). However, 
the A1 inhibitor was ineffective in the MCF7 cells. Since the A5 inhibitor was successful in 
decreasing the cell growth rate of PC-12 EV, T47D, and MCF7 cells, it is recommended for use 
in all future studies involving HSD10 inhibition. 
Additionally, it is suggested that the MCF7 breast cancer cell line be retained as an 
alternative to the T47D breast cancer cell line for future in vivo HSD10 inhibitor studies, as 
MCF7 cells behave similarly to T47D cells (165).  
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Figure 3-6: Effect of HSD10 inhibition on in vitro MCF7 cell growth. MCF7 wild-type cells 
were plated at a constant density and treated with either 100 μM A1 or 100 μM A5 HSD10 
inhibitors. The cells were then grown and counted over the course of 10 days to determine cell 
growth rate. Growth curve of untreated control (■, solid line) versus either A1-treated (♦, dashed 
line) or A5-treated (▲, dotted line) displayed as cells x 10
4
 per ml (n=4). Data presented as mean 
± SE. #P<0.05, ##P<0.01 versus control group for A1 inhibitor; *P<0.001, **P<0.0001 versus 
control group for A5 inhibitor. 
 
Studies with HSD10 inhibitors must be performed in vivo to assess the efficacy of 
HSD10 inhibition on reducing tumor formation and growth rate in animals. These experiments 
would provide clinically relevant data regarding the pharmacological capabilities of HSD10 
inhibitors in cancer treatment.  
Additionally, since blocking enzymes can yield different consequences as opposed to 
reducing protein, cell culture studies need to be completed to investigate the mechanism of 
action for the HSD10 inhibitors. TUNEL staining utilizing wild-type breast cancer cells, such as 
T47D, and the compounds will assess whether inhibition of HSD10 promotes cancer cell death.  
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This would suggest that the HSD10 inhibitors slow cancer cell growth rate and tumor 
formation by inducing cell death. If no significant changes are observed, cell-cycle analysis 
using flow cytometry should be used to determine if inhibition of HSD10 affects cell 
proliferation. This would indicate that the HSD10 inhibitors hinder cancer cell growth and tumor 




















3.4. Interim Conclusion 
Chapter 3 discussed future directions for the project investigating HSD10 in cancer 
progression. Using stably-transfected cells lines with HSD10 overexpression or HSD10 
knockdown, it was recommended that all assays and experiments detailed in Chapters 1 and 2 
be performed in the human breast cancer cell lines. This will provide the necessary human-
specific data for confirmation of the role of HSD10 in breast cancer.  
Moreover, several mechanistic studies involving the interaction between HSD10 and 
CypD were outlined, including Co-IP, CypD translocation, and cell death assays utilizing 
HSD10-modified as well as CypD-modified human breast cancer cell lines. Further investigation 
into the relationship between HSD10 and CypD will elucidate the mechanism underlying the 
growth rate and cellular functional phenotypes initially observed in the PC-12 cells. 
Finally, experiments with the HSD10 compounds were suggested, as they may produce 
clinically relevant data regarding the potential use of HSD10 inhibitors as anti-cancer 
therapeutics (Fig. 3-7). These studies would provide an important foundation for targeting 
HSD10 as a novel cancer treatment.   
 
 
Figure 3-7: Chapter 3 summary of the future outlook for HSD10 inhibition in cancer.  
In cancer cells, HSD10 levels correlate with HSD10-CypD complex formation, mitochondrial 
membrane stabilization, and heightened energy production, which leads to cancer cell survival 
through enhanced cellular resistance to cell death. Upon HSD10 inhibition, cancer cell growth 




This study demonstrated for the first time that PC-12 pheochromocytoma cells 
overexpressing HSD10 grow significantly faster in cell culture and form larger tumors at a faster 
rate in SCID mice. It was theorized that HSD10 promotes enhanced cell growth through altered 
mitochondrial function, as enhanced complex IV enzyme activity and ATP production in PC-12 
cells overexpressing HSD10 was observed. Knockdown of HSD10 negatively impacted PC-12 
cell growth and mitochondrial function; all ETC complex activities were considerably reduced, 
as well as ATP generation. This diminished energy production is likely responsible for the 
reduced growth rate observed in cell culture. The possibility that HSD10 may confer protection 
in cancer cells was also evaluated. Upregulation of HSD10 permitted PC-12 cells to maintain a 
higher functional capacity with reduced cell death induction under chemical-induced oxidative 
stress. Knockdown of HSD10 reversed PC-12 cellular resistance capabilities, which led to 
heightened cell death induction under baseline and oxidative stress conditions. 
Additionally, the mechanism of action underlying the phenotype observed following 
HSD10 modification was investigated by assessing the interaction of HSD10 with CypD. In 
HSD10-overexpressing PC-12 cells, enhanced complex formation was observed between HSD10 
and CypD using co-IP, which possibly explains the lower cell death induction rate in cells with a 
surplus of HSD10. Knockdown of CypD in PC-12 cells overexpressing HSD10 resulted in a 
trend toward lower cell growth rate, but no changes in energy metabolism, suggesting that the 
slight decrease in proliferation is due to cell death. As expected, knockdown of CypD in PC-12 
cells overexpressing HSD10 revealed an increase in cell death induction under oxidative stress 
conditions compared to matched control cells. 
122 
Next, this phenomenon was investigated in four human breast cancer cell lines in order to 
broaden the scope of cancers that are potentially influenced by HSD10. MCF10A breast cells, as 
well as MCF7 and MDA-MB-231 breast cancer cells were modified to overexpress HSD10, 
while T47D breast cancer cells were altered to lower HSD10 levels. Overexpression of HSD10 
did not alter the growth rate of either the MCF10A or MDA-MB-231 cells. In MCF7 cells, 
HSD10 overexpression resulted in a slight trend toward increased cell growth rate, although not 
in a statistically significant way. Nevertheless, HSD10 knockdown significantly reduced T47D 
cell growth rate. Similar to the PC-12 cells, lowering of HSD10 levels in the T47D cells reduced 
complex IV enzyme activity and ATP production, indicating that the phenotype of HSD10 
knockdown is sustained across two different cancers. 
Taken together, these findings provide evidence that HSD10 mediates cancer cell growth 
and resistance to death-inducing environments via interaction with CypD. This section will 












In Vivo Mouse Model 
The use of an in vivo xenograft mouse model demonstrated that PC-12 HSD10-
overexpressing cells grew faster and formed larger tumors over 32 days, as opposed to vector 
control tumors (Fig. 1-4). While there are limited in vivo xenograft studies involving PC-12 
cells, Freed et al. revealed that following implantation of PC-12 cells into the striatum of 
Sprague-Dawley rats, the number of cells remained unchanged over 20 weeks without continued 
tumor growth (158). This is consistent with the minimal growth observed in PC-12 EV tumors 
and provides further support for the tumor-promoting capability of HSD10. 
Due to the inability of PC-12 EV cells to form measureable tumors in vivo, it was 
unrealistic to establish a xenograft mouse model using PC-12 cells to assess the effect of HSD10 
knockdown on tumor growth. While animal data is lacking for the effect of HSD10 knockdown 
on PC-12 tumor formation, the cell culture evidence strongly shows that reduction of HSD10 is 
accompanied by deficits in energy metabolism, cell growth, and resistance to cell death in PC-12 
and T47D cells. Hence, it is predicted that HSD10 knockdown will limit tumor growth in vivo.  
As outlined in Chapter 3, stable HSD10 knockdown in T47D cells would provide a 
suitable foundation for analysis of tumor growth in vivo, as this cell line forms consistent, slow-
growing tumors within three to six months (164). The use of T47D cells is also highly 
recommended for in vivo studies assessing the efficacy of HSD10 inhibitors, as HSD10-
overexpressing PC-12 cells showed little to no change in tumor growth between vehicle-treated 
and HSD10 inhibitor-treated animals (Fig. 3-4). As the PC-12 HSD10 overexpression cells 
demonstrate exceptionally high metabolic and replication rates, it is anticipated that the tumors 
will be largely unresponsive to HSD10 inhibition in vivo. Thus, this cell line is not a good choice 
for the additional in vivo studies pertaining to this project. 
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Effect of HSD10-Alteration on Cancer Cell Function 
Cell Proliferation and Energy Metabolism 
Typically, tumors exhibit increased cell proliferation compared to noncancerous tissues. 
Similarly, HSD10-overexpressing PC-12 cells demonstrated an enhanced cell growth rate in cell 
culture (Fig. 1-3 A). This phenomenon is likely due to altered processes within mitochondria, as 
large amounts of HSD10 localized with mitochondria in HSD10-overexpressing cells. Although 
the Warburg effect of elevated glycolytic ATP production in cancer cells is widely recognized 
(7), many groups have revealed that mitochondria in tumor cells are able to operate both 
respiratory pathways (34). As elevated ATP production was observed in HSD10-overexpressing 
cells (Fig. 1-7), it is possible that HSD10 provides additional energy metabolites for the cells. 
Among its many functions, HSD10 is involved in the breakdown of fatty acids and 
branched chain amino acids, primarily isoleucine. In the isoleucine metabolism pathway, HSD10 
catalyzes the NADH-dependent oxidation of 2-methyl-3-hydroxybutyryl-CoA to 2-methyl-
acetoacetyl-CoA (115, Schematic 8). The end products, acetyl-CoA and propionyl-CoA, are 
then used in the TCA cycle to generate ATP. 
 β-oxidation is also a source of ketone bodies that can provide energy for the liver (170), 
heart (171), brain (172), and other organs when glucose levels are low. When glycolysis is 
inhibited, two acetyl-CoA molecules condense to form acetoacetyl-CoA, which then forms into 
the ketone bodies, acetoacetate and BHB (173). These substrates can then be taken up by 
mitochondria where they are reconverted to acetyl-CoA and used to fuel the TCA cycle (174). 
Although HSD10 does not play an essential role in ketone metabolism under physiological 
conditions, Yan et al. suggests that it may assist the mitochondrial enzyme normally responsible 
for BHB oxidation, β-hydroxybutyrat-dehydrogenase, under cellular stress situations (127). 
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Schematic 8: Role of HSD10 in the isoleucine metabolism pathway. Isoleucine is metabolized 
in several steps via different enzymes. HSD10 catalyzes the NADH-dependent oxidation of 2-
methyl-3-hydroxybutyryl-CoA to 2-methyl-acetoacetyl-CoA. End products are acetyl-CoA and 
propionyl-CoA which are vital substrates for other metabolic pathways involved in the 
production of ATP. Adapted from Zschocke, J. et al. (2000) Pediatr Res (113). 
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Studies have shown that tumor animal models utilize BHB as an energy source. For 
instance, Kallinowski et al. observed that BHB concentrations increased in the tumors of nude 
rats as tumor blood flow decreased (175). Additionally, Pavlides et al. recently discovered that 
BHB is upregulated in caveolin-1 null mice and proposed that epithelial cancer cells directly take 
in stromal-derived BHB to drive tumor progression and eventual metastasis (176). With cancer 
cells already displaying heightened ATP generation, the addition of another source of energy via 
the enzymatic capability of HSD10 would enhance energy production even further. This could 
lead not only to alterations in mitochondrial bioenergetics, but also to changes in mitochondrial 
signal transduction pathways, including resistance to cell death. 
ETC complex IV enzyme activity was also increased in the PC-12 HSD10-
overexpressing cells (Fig. 1-5 D), likely contributing to the ability of ATP synthase to generate 
additional ATP. The increase seen in complex IV, but not observed in complex I-III, could be 
attributed to the rate-limiting capability of complex IV (177). The enhanced energy production 
implies that mitochondrial processes are highly functional in the PC-12 cells with HSD10 
overexpression. This was further verified by the consistent enzymatic activity of citrate synthase 
(Fig. 1-8) and enhanced mitochondrial membrane potential (Fig. 1-9 B-C). Hyperpolarization of 
the mitochondrial membrane in HSD10-overexpressing PC-12 cells would aid in the protection 
against membrane depolarization and cell death induction, thereby permitting mitochondria to 
continue generating energy to fuel cell growth. 
Conversely, HSD10-underexpressing PC-12 and T47D cells both exhibited decreased cell 
growth rate in cell culture (Fig. 1-3 B and Fig. 2-6 B, respectively). This phenotype is likely due 
to the deficits observed in several mitochondrial processes. All ETC complex enzyme activities 
were significantly diminished following HSD10 knockdown in the PC-12 cells (Fig. 1-5), as 
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well as complex IV enzyme activity in the T47D HSD10-underexpressing cells (Fig. 2-7 D). 
Additionally, cellular ATP levels were reduced in the PC-12 HSD10 knockdown cells (Fig. 1-7) 
and T47D HSD10 knockdown cells (Fig. 2-8). Taken together, these findings indicate that 
reduction of HSD10 disrupts cancer cell mitochondrial function and structure.  
Furthermore, loss of endogenous HSD10 could be considered a stressor in cancer cells, as 
it was accompanied by decreased citrate synthase enzyme activity in the PC-12 HSD10-
underexpressing cells (Fig. 1-8). As citrate synthase is a pacemaker enzyme in the TCA cycle, it 
is commonly used as a quantitative marker enzyme to assess the content of intact mitochondria 
(178, 179). Therefore, the reduction in citrate synthase enzyme activity indicates that the PC-12 
HSD10 knockdown cellular mitochondria are dysfunctional under baseline conditions. This was 
further confirmed after examination of the mitochondrial membrane potential using TMRM dye, 
which revealed that fewer PC-12 HSD10 knockdown mitochondria had intact membranes (Fig. 
1-9 D-E). In accordance with other studies, TMRM provided accurate results under the non-
quench mode used in the experiment (180-182). Thus, HSD10 reduction correlated with 
diminished energy production, which was likely caused by mitochondrial energy metabolism 
disruption and membrane potential loss. 
Also, cell viability was examined using the MTT reduction assay, which utilizes the 
reduction of MTT by NADH in the cytoplasm to measure metabolic activity (183). It is presently 
understood that the amount of MTT formazan product is proportional to the number of living 
cells (184). No significant changes were observed between all PC-12 cell groups at baseline, 
although there was a slight trend toward decreased MTT reduction in HSD10 knockdown cells 
(Fig. 1-9 A). This result suggests that the changes seen in the ETC complexes and ATP 
production are due to differences in PC-12 cell growth rate, and not cell death induction.  
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However, the significance of the MTT reduction assay has been seriously questioned 
recently (185), as there is a high rate of variability, including undetected toxicity or false 
proliferation results (186). Such inconsistences are likely caused by variable assay conditions 
which can alter metabolic activity, and consequently the MTT dye reduction without affecting 
cell viability (187). Furthermore, changes in baseline and stress-induced cell death were 
observed in the PC-12 HSD10-transfected cells, calling into question the PC-12 MTT assay 
findings. Duplication of the experiment may provide insight into the MTT assay data, or it may 
yield inconstant results. Alternative cell viability assays that would likely provide more reliable 
results include the protease viability marker assay (188) and the ATP assay (189), which was 
utilized in this thesis.   
 
Cellular Resistance to Stress Stimuli and Cell Death 
In addition to heightened cell proliferation, tumors often display enhanced resistance to 
cell death when compared to noncancerous tissues. Correspondingly, HSD10-overexpressing 
PC-12 cells demonstrated increased resistance to oxidative stress-induced cell death (Fig. 1-11 
A-B) compared to matched control cells. This phenotype is likely caused by the hyperpolarized 
mitochondrial membrane, which grants HSD10-overexpressing PC-12 mitochondria the ability 
to maintain higher functioning processes, such as energy metabolism (Fig. 1-10 C-D), during 
death-inducing situations compared to matched controls. 
The MTT reduction assay was also used to assess cell viability under oxidative stress 
conditions, namely H2O2 and TBH (Fig. 1-10 A and B, respectively). The results were similar to 
the ETC complex IV enzyme activity data (Fig. 1-10 C-D), indicating that overexpression of 
HSD10 confers PC-12 cells protection against stress-induced cellular dysfunction. However, as 
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mentioned previously, the MTT assay as a viability assay is under debate (185, 186). Thus, it 
must be stated that the MTT results alone would be considered debatable. Nevertheless, the 
additional experiment examining complex IV enzyme activity under stress conditions provides 
further support for the resistance phenotype of the PC-12 HSD10 overexpression cells. 
While the TUNEL assay is a well-accepted histological method for cytotoxicity via 
detection of apoptotic cells (190), it has various limitations. For instance, cells undergoing active 
gene transcription can yield false-positive TUNEL results (191). Also, several studies have 
shown that TUNEL cannot always distinguish between cells undergoing apoptosis and necrosis 
(192, 193). Hence, other cytotoxicity assays, such as caspase-3 activity (194) or Annexin V 
(195), should be used in combination with TUNEL to validate apoptotic cell death. Additionally, 
it would be beneficial to evaluate whether HSD10 overexpression impacts necrotic cell death, 
thus determining the favored cell death pathway involved. The measurement of LDH release is a 
useful approach for the detection of necrosis, and would provide the necessary evidence 
pertaining to which cell death pathway is involved in the HSD10-modificed cells (196). 
Likewise, autophagy should be examined in relation to HSD10-modification, as many cancer 
cells exhibit defective autophagy which can promote tumor growth despite cellular stress (197). 
Immunoblotting and immunofluorescence can be employed to detect the endogenous levels of 
autophagy-related proteins, including LC3-I, LC3-II, and Beclin-1. Inhibitors, such as 
Bafilomycin A1, which block the degradation of autolysosome content, should also be used to 
assess autophagic flux (198). 
On the contrary, HSD10-underexpressing PC-12 cells exhibited decreased resistance to 
oxidative stress-induced cell death (Fig. 1-11 C-D), conceivably due to deficits in the 
mitochondrial membrane potential and energy metabolism. Indeed, PC-12 cells with HSD10 
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knockdown displayed reduced complex IV enzyme activity under both baseline and oxidative 
stress conditions (Fig. 1-10 E), providing additional evidence that reduction of HSD10 disrupts 
cancer cell mitochondrial function and cell death resistance capabilities.  
Similar to the PC-12 HSD10 overexpression data, additional cytotoxicity experiments are 
necessary to confirm the increased stress-induced apoptotic induction shown by TUNEL staining 
in the PC-12 HSD10 knockdown cells. Also, an LDH release assay would provide evidence as to 
whether the necrotic cell death pathway is implicated following HSD10 knockdown. 
Furthermore, the endogenous levels of autophagy-related proteins should be examined via 
immunoblotting and immunofluorescence to investigate if autophagy is impacted by HSD10 
knockdown. Moreover, an MTT assay was not performed to assess cell viability in the PC-12 
HSD10-underexpressing cells treated with H2O2. While the MTT assay alone may have 
limitations, it would further solidify the complex IV enzyme activity findings. Other cell 
viability assays, such as the protease viability marker assay previously mentioned, would also 
provide added support. 
Overall, the PC-12 cellular data indicate that HSD10 is an important component 
underlying cancer cell resistance to cell death. Upon the introduction of a death-inducing 
stimulus, cancer cells with an abundance of HSD10 remain highly functional (Schematic 9.1) 
and less susceptible to cell death (Schematic 9.2). In contrast, cancer cells with low levels of 
HSD10 are more prone to mitochondrial dysfunction (Schematic 9.3) and less resistant to cell 




Schematic 9: Consequence of HSD10 expression in cancer cells under death-inducing 
conditions. Cancer cells overexpressing HSD10 are 1) able to maintain a high state of energy 
metabolism and 2) prevent MPTP-mediated apoptosis via interaction with CypD under oxidative 
stress situations. Conversely, cancer cells with reduced levels of HSD10 are 3) unable to produce 











Role of HSD10-CypD Interaction in Cancer 
In Chapter 1, it was proposed that the phenotype observed in the PC-12 HSD10 
overexpression cells was caused by increased binding with CypD. In the PC-12 cells, CypD 
protein levels remained constant despite overexpression of HSD10 (Fig. 1-12 A-B). This result 
was rather unexpected as CypD is often overexpressed in certain cancers (83, 160). 
Theoretically, overexpression of HSD10 would have a limited effect on CypD expression, as 
CypD protein is already abundant in cancer cells. Furthermore, Co-IP revealed an enhanced 
interaction between HSD10 and CypD in PC-12 HSD10-overexpressing cells compared to match 
control cells under baseline conditions (Fig. 1-14). Due to the evidence demonstrating that the 
PC-12 HSD10-overexpressing cells were more resilient against stress-induced cell death, 
assessing the effect of oxidative stress on the HSD10-CypD interaction would strengthen the role 
of HSD10 and CypD in cancer progression and aggressiveness. 
 Co-IP is a commonly used method for examining protein-protein interactions (199, 200); 
however, it has a few limitations that must be addressed. For instance, the use of complex 
mixtures, instead of purified proteins, can make it difficult to determine that the two proteins-of-
interest bind to one another directly (201). Moreover, Co-IP cannot yield quantitative data 
pertaining to the affinity of interactions (202). Also, Co-IP data has been mainly used for 
detection of interactions between pairs of proteins, not co-complex relationships. Geva et al. 
recently devised a novel way for analyzing whole protein complex detection from Co-IP results 
by detecting sets of prey that co-associate with the same set of baits (203). As both HSD10 and 
CypD have been shown to bind other factors, this method would provide important information 
regarding a possible complex formation involving HSD10, CypD, and other factors, such as Bcl-
2 (58), HK-II (59), or ER (150). 
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In contrast to the unchanged expression in the PC-12 HSD10-overexpressing cells, 
knockdown of HSD10 correlated with reduced CypD protein expression (Fig. 1-12 C-D), which 
indicates that CypD levels are negatively affected by HSD10 reduction in cancer cells. Since the 
TUNEL assay demonstrated that the PC-12 HSD10 knockdown cells were more vulnerable to 
both baseline and stress-induced cell death, Co-IPs would be essential for evaluation of the effect 
of HSD10 knockdown at baseline and under oxidative stress conditions on the HSD10-CypD 
interaction. Performing Co-IPs in the PC-12 cells with HSD10 reduction would provide 
necessary data to further elucidate the role of HSD10 and CypD in cancer. 
Next, the effect of CypD knockdown in the PC-12 HSD10-overexpressing cells was 
investigated. Reduction of CypD was accompanied by a decrease in HSD10 protein content in 
the PC-12 HSD10 overexpression cells (Fig. 1-15 A-B), matching the previously mentioned 
results showing that HSD10 reduction correlates with reduced CypD expression in wild-type PC-
12 cells. This data strengthens the hypothesis that HSD10 and CypD are connected in cancer. 
However, knockdown of CypD did not significantly alter PC-12 HSD10-overexpressing cell 
growth (Fig. 1-16), although a small trend toward decreased growth rate was observed. This data 
suggests that HSD10 could be a potential upstream modulator controlling CypD-induced 
mitochondrial perturbation. 
Several explanations are possible for this result. First, it is likely that the PC-12 HSD10-
overexpression cells are a poor model for assessing the role of factors other than HSD10. The 
extreme proliferative capabilities observed in this particular cell line are undoubtedly promoted 
by the artificial overexpression of HSD10 itself. Wild-type PC-12 cells would provide a 
favorable alternative for the evaluation of CypD knockdown, as HSD10 levels would be natural. 
Second, it is possible that the use of siRNA to knockdown CypD was ineffective for the duration 
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of the cell growth curve experiment (166). While the small difference in growth rate between the 
control and CypD knockdown cells is observed, it does not shift further apart, suggesting that the 
siRNA-mediated gene silencing may not be effective. For a short-term experiment, lentiviral 
transfection using shRNA to knockdown CypD could be employed to determine the effect on 
cell growth rate (167). Third, it is feasible that CypD knockdown does not affect cell growth rate 
due to intracellular changes. Mitochondrial bioenergetics and/or signal transduction pathways, 
such as apoptosis, may be altered upon CypD knockdown as a compensatory mechanism to 
maintain mitochondrial function and protect the affected cancer cells. 
As there was a trend, but no significant difference, toward decreased cell growth rate 
following CypD knockdown in the PC-12 HSD10-overexpressing cells, it was not surprising that 
cellular energy metabolism processes were unaffected (Fig. 1-17 A-B). Since CypD is involved 
in cell death induction, it is possible that loss of CypD does not directly impact the mitochondrial 
energy production processes. Recently, several groups have discovered that CypD deficiency 
prevents diet-induced obesity by increasing glucose metabolism and ATP production in mice 
(204, 205). Additionally, Shulga et al. demonstrated that inactivation of CypD promotes the 
detachment of HKII from the MPTP, leading to the stimulation of mitochondrial bioenergetics in 
cancer cells (206). This evidence suggests that knockdown of CypD promotes mitochondrial 
bioenergetics, thereby providing an additional explanation for the consistently high, unaltered 
energy metabolic results. Furthermore, the HSD10 overexpression phenotype of the PC-12 cell 
line aids in the maintenance of high functioning mitochondrial bioenergetics, in addition to the 
consequence of CypD knockdown. As these mitochondria are already functioning at a higher 
capacity than wild-type PC-12 cells, it is logical that knockdown of CypD would not provide a 
synergistic affect.  
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The energy metabolism results indicate that despite the reduction of CypD, the PC-12 
HSD10-overexpressing cells still exhibit similar functional rates, which correlate with similar 
cell growth rates. However, since a small trend toward decreased cell growth rate was observed 
in the CypD knockdown cells, a TUNEL assay was performed to examine cell death induction. 
The control PC-12 HSD10-overexpressing cells and CypD knockdown PC-12 HSD10-
overexpressing cells both showed low percentages of apoptotic cells at baseline (Fig. 1-18 B). 
The CypD knockdown group exhibited a slight trend toward increased cell death induction 
versus the control group, although this trend was not statistically significant. However, despite 
the lack of statistical significance, the trend of slightly increased cell death under baseline 
conditions matches the trend of marginally lowered cell growth rate at baseline for the CypD 
knockdown PC-12 HSD10-overexpressing cells. Thus, it is logical that the slightly reduced cell 
growth rate is due to a minor elevation in cell death induction, at baseline conditions. 
Under an oxidative stress situation, reduction of CypD rendered the PC-12 HSD10-
overexpressing cells more vulnerable to cell death induction in comparison to the control PC-12 
HSD10-overexpressing cells (Fig. 1-18 B). This indicates that regardless of the presence of 
HSD10, the PC-12 cells with less CypD were more susceptible to stress-induced apoptosis. 
However, this phenomenon is a bit incongruous with the overall hypothesis of this thesis. If 
CypD levels are reduced, theoretically, HSD10 levels are reduced to a similar degree, as 
demonstrated via immunoblotting (Fig. 1-15 B). Logically, the remaining CypD may still be 
bound to HSD10, thereby preventing CypD from inducing MPTP-mediated cell death. However, 
increased cell death is observed under stress conditions following CypD and HSD10 lowering. 
One possibility is that small amounts of unbound CypD are able to translocate to the IM and 
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induce cell death (Schematic 10.2). This is logical, as HSD10 is able to bind to many different 
substrates, thereby providing CypD with a limited opportunity to function independently. 
Alternatively, the results advocate a different mechanism of action that involves a super-
complex of proteins. As CypD interactions with other proteins, such as Bcl-2 (58) and HK-II 
(59), have been observed to prevent apoptosis in cancer cells, it is possible that a super-complex 
exists between HSD10, CypD, Bcl-2, HK-II, and potentially other mitochondrial proteins 
(Schematic 10.1). For example, if the expression of HK-II is unchanged when HSD10 and CypD 
levels are reduced, it is hypothetical that unbound HK-II molecules are able to induce pro-
apoptotic Bax/Bak-mediated cell death under stress situations (Schematic 10.3). Co-IPs would 
be necessary to investigate the possibility of a super-complex between these proteins, prior to 




Schematic 10: Hypothetical super-complex of HSD10, CypD, Bcl-2, HK-II, and/or other 
proteins. Cancer cells overexpressing HSD10 and CypD are 1) able to form a super-complex 
with Bcl-2, HK-II, and possibly other proteins to prevent apoptosis under death-inducing 
conditions. In the event of HSD10 and CypD protein loss in cancer cells, 2) other components of 
the super-complex are released, such as HK-II, which can mediate cell death induction in 










Potential Role of HSD10-ER Interaction in Breast Cancer 
It was postulated in Chapter 2 that the unchanged phenotype of the MDA-MB-231 
breast cancer cells after lentiviral HSD10 overexpression (Fig. 2-6 C) was due to the triple 
negative status of the cell line. MDA-MB-231 cells do not express ERs, progesterone receptors, 
or human epidermal growth factor receptor 2 (207). As HSD10 belongs to the HSD17B family 
which catalyzes the interconversion of dehydroepiandrosterone (DHEA) to androstanediol 
(adiol), androstenedione to testosterone, and estrone to E2, respectively (208, Schematic 10), it 
is possible that the role of HSD10 in cancer progression is specific to hormone-related tumors. 
 Currently, four publications have examined HSD10 in cancer. He et al. demonstrated that 
certain malignant prostate cells with increased HSD10 expression are able to generate higher 
amounts of dihydrotestosterone (DHT) from adiol, compared to control cells (118). Since DHT 
is the most potent androgen, HSD10 overexpression may promote prostate cancer growth via the 
favored conversion of adiol to DHT. Additionally, Salas et al. found that HSD10 gene expression 
was up-regulated in osteosarcoma patients categorized as poor responders to chemotherapy 
(148). Androgens and estrogens have been linked with bone tumor incidence (209-211), 
indicating a role for HSD10 with steroids in a variety of cancer types. Connecting these findings, 
Jernberg et al. showed that prostate-to-bone metastases expressed higher levels of HSD10 
compared to non-malignant prostate and primary prostate tumor tissue (149), which may provide 
cells with the capacity to convert larger quantities of androgens into more potent androgens, thus 
promoting cancer growth and aggressiveness. 
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Schematic 11: Role of HSD10 in the steroidogenesis pathway. During steroidogenesis, 
members of the HSD17B family catalyze the interconversion of dehydroepiandrosterone 
(DHEA) to androstanediol (adiol; gold bar), androstenedione to testosterone (blue bar), and 
estrone to estradiol (E2; pink bar). The HSD17B family can also catalyze the oxidation of adiol 




Lastly, Carlson et al. demonstrated that PC-12 cells overexpressing HSD10 exhibit 
increased cell growth rate and resistance to stress-induced cell death (152). PC-12 cells do not 
express ERα (213); nevertheless, ERβ protein has been detected in the cells, albeit minimal 
expression (214). Interestingly, it was previously discovered by Nilsen et al. that PC-12 cells 
express both ERα and ERβ upon nerve growth factor treatment (215), suggesting that cell 
stimulation could induce ER expression. Moreover, Charalampopoulos et al. showed that 
androgen receptors specific for DHEA are present on the membrane surface of PC-12 cells 
(216), providing further evidence for an involvement of HSD10 with steroids in cancer. 
Since the future goal of the project is to examine HSD10 in breast cancer, the remainder 
of this section will predominantly focus on the potential role of estrogen with HSD10. While 
both ER subtypes are expressed in the cardiovascular system, immune system, nervous system, 
and reproductive system of humans, ERα is predominantly expressed in the reproductive system 
(217) whereas ERβ is largely expressed in the nervous system (218). Of the four breast cancer 
cell lines used in this dissertation, T47D and MCF7 cells are ER-positive (219), while MCF10A 
and MDA-MB-231 cells are ER-negative (220). 
It is widely recognized that estrogens play a major role in promoting breast epithelial cell 
proliferation (221, 222). Accordingly, the role of estrogen as a breast carcinogen is under active 
investigation. It has been postulated that estrogens induce tumorigenic effects through binding to 
ERα (223). Acting through ERα would allow estrogens to exert a potent stimulus on breast cell 
growth via actions on the enhanced production of growth factors (224). However, as reported in 
a recent study, ERα knockout mice expressing the Wnt-1 oncogene still developed mammary 
tumors, indicating that estrogens may cause breast cancer through a non-ERα-mediated 
mechanism, such as genotoxicity (225, 226). 
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As specified, HSD17B catalyzes the interconversion of estrone and E2 (208). A highly 
potent estrogen, the carcinogenicity of E2 has been successfully demonstrated by the 
transformation of human breast epithelial cells (227, 228). This supports the concept that E2 can 
act as a carcinogenic agent without the presence of ERα. Nevertheless, it is possible that ERβ or 
other mechanisms could play a role in the transformation of human breast epithelial cells. 
HSD10 was observed to bind to ERα in rat cardiomyocyte mitochondria (150), which 
inhibited the conversion of E2 to estrone. It is possible that in breast cancer cells, as well as other 
hormone-dependent cancers, HSD10 forms a complex with ERα, thereby disrupting the 
conversion of highly toxic E2 to less potent estone. Without free HSD10 to catalyze the reaction, 
E2 accumulates in the breast cancer cells and stimulates uncontrolled cell proliferation. This 
event may underlie hormone-dependent cancer cell growth, which may provide a novel avenue 
for hormone therapy involving HSD10. Further research is necessary to specify which ERs 













The results presented in this thesis provide a promising platform for further research to 
elucidate the mechanism underlying HSD10-mediated cancer cell growth and cell death 
resistance. As HSD10 overexpression granted pheochromocytoma cells enhanced cellular 
proliferative and cell death resistant capabilities, targeted inhibition of HSD10 in cancer cells 
may provide a novel treatment method. Furthermore, since lowering of HSD10 in 
pheochromocytoma cells was accompanied by increased vulnerability to stress-induced 
apoptosis, simultaneous application of a HSD10-specific inhibitor with current anti-cancer 
therapies that induce cell death may afford an effective combinatorial treatment. Classic options 
of cytotoxic agents include cisplatin (229), etoposide (230), paclitaxel (231), or doxorubicin 
(232). Also, CypD knockdown in pheochromocytoma cells with overexpression of HSD10 
rendered the cells more susceptible to stress-induced cell death; thus, manipulation of CypD may 
deliver an additional way of treating cancer patients. 
Furthermore, after verifying that HSD10 is important in rat adrenal gland tumor cell 
growth, the subsequent step was to investigate its role in human cancers. HSD10 knockdown 
reduced T47D breast cancer cell growth rate and was accompanied by decreased energy 
production, providing a compelling start toward examining HSD10 in human breast cancer. The 
effect of HSD10 in breast cancer development will be especially compelling as HSD10 is able to 
regulate estrogen steroidogenesis (125). Furthermore, fellow HSD10 family member HSD17B 
type 1 was discovered as a novel target for endocrine therapy in certain breast cancer patients 
(233-235). Thus, evaluating the effect of HSD10 on human cancers would then provide vital 
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